Purine Derivatives and Their Use as Anti-Coagulants

专利摘要:
The present invention relates to purine derivatives useful as anticoagulants. The invention also relates to pharmaceutical compositions containing the compounds of the invention and methods of treating disease states characterized by thrombotic activity using said compounds.
公开号:KR20000068177A
申请号:KR1019997001289
申请日:1997-08-14
公开日:2000-11-25
发明作者:마이클 엠. 모리세이；브래드 버크만；라주 모한
申请人:에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만；쉐링 악티엔게젤샤프트；
IPC主号:

专利说明:

Purine Derivatives and Their Use as Anti-Coagulants
Factor Xa is a member of the trypsin serine protease class enzyme. Factors Xa and Va bind one-to-one with calcium ions and phospholipids to form prothrombinase complexes that convert prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin, which polymerizes to form insoluble fibrin.
In coagulation cascades, the prothrombinase complex is the point of convergence of intrinsic (surface activated) and external (by vascular injury tissue factor) pathways (Biochemistry, (1991), Vol. 30, p.10363; and Cell , (1988), Vol. 53, pp 505-518). The coagulation cascade model was refined by discovering a model of action of tissue factor pathway inhibitors (TFPI) (Seminars in Hematology, 1992, Vol. 29, pp 159-161). TFPI is a circulating multidomain serine protease inhibitor with three Kunitz-like domains, competing with factor Va for free factor Xa. Once formed, the binary complex of factor Xa and TFPI is a potent inhibitor of factor VIIa and tissue factor complexes.
Factor Xa can be activated by two different complexes, the tissue factor-VIIa complex on the "Xa burst" pathway in the coagulation cascade and the Factor IXa-VIIIa complex of the "persistent Xa" pathway. . After vascular injury, the "Xa-burst" pathway is activated through tissue factor (TF). Synergistic regulation of coagulation cascades is caused by increased factor Xa production through the "continuous Xa" pathway. Reduced regulation of the coagulation cascade not only results in factor Xa-TFPI complex formation, which eliminates factor Xa, but also further inhibits factor formation through the "Xa burst" pathway. Thus, coagulation cascades are naturally regulated by factor Xa.
The primary advantage of the inhibition of factor Xa on thrombin to prevent clotting is the pathological function of factor Xa over multiple functions of thrombin. Thrombin not only catalyzes the conversion of fibrinogen to fibrin, factor VIII to VIIIa, factor V to Va, and factor XI to XIa, but also activates platelets, is a monocyte chemotactic factor, and mitogen for lymphocytes and smooth muscle cells to be. Thrombin binds to thrombomodulin to activate protein C, an in vivo anticoagulant inactivator of factors Va and VIIIa. Circulating thrombin is rapidly inactivated by antithrombin III (ATIII) and heparin cocatalyst II (HCII) in catalysis by heparin or other proteoglycan related glycosaminoglycans, while thrombin in the tissue is a protease Inactivated by Nexin. Thrombin is via a unique "tethered ligand" thrombin receptor (Cell (1991), Vol. 64, p. 1057) and requires the same anion binding site and activation site used for fibrinogen binding and cleavage, and thrombin It performs its multi-cell activation function by bomodulin binding and protein C activation. Thus, various groups of target molecules in vivo compete for binding to thrombin, and subsequent proteolytic processes may have a wide variety of physiological significance depending on the cell type and the receptor, modulator, substrate or inhibitor that binds to thrombin. will be.
Published data on anti-clotting proteins and tick anticoagulant peptides (TAPs) demonstrate that factor Xa inhibitors are effective as anticoagulants (Thrombosis and Haemostasis (1992), Vol. 67, pp371-376; and Science ( 1990), Vol. 248, pp. 593-596).
The activation site of factor Xa may be blocked by a mechanism based or strong binding inhibitor (strong binding inhibitors differ from the mechanism based inhibitor by the absence of covalent bonds between the enzyme and the inhibitor). Two types of mechanism based inhibitors are known that are reversibly and irreversibly distinguished by the ease of hydrolysis of enzyme-inhibitor bonds (Thrombosis Res (1992), Vol. 67, pp. 221-231; and Trends Pharmacol. Sci. (1987), Vol. 8, pp. 303-307). A series of guanidine compounds are one example of potent binding inhibitors (Thrombosis Res. (1980), Vol. 19, pp. 339-349). In addition, 3-amidinoferylaryl derivatives (Thrombosis Res. (1983), Vol. 29, pp. 635-642) and bis (amidino) benzyl cycloketones (Thrombosis Res. (1980), Vol. 17, pp. In addition to a series of arylamide containing compounds, including 545-548, arylsulfonyl-arginine-piperidine-carboxylic acid derivatives are shown as strong binding inhibitors (Biochem (1984), Vol. 23, pp. 85-90). ). However, these compounds show low selectivity for factor Xa.
<Related disclosures>
EP 0 540 051 (Nagahara et al.) Describes aromatic amidine derivatives which can exhibit potent anticoagulant effects through reversible inhibition of factor Xa.
α, α'-bis (amidinobenzylidene) cycloalkanones and α, α'-bis (amidinobenzyl) cycloalkanones are described in Pharmazie (1977), Vol. 32, no. 3, pp. 141-145. The compound is disclosed as a serine protease inhibitor.
<Summary of invention>
The present invention relates to a compound or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating a disease state characterized by thrombotic activity by inhibiting factor Xa in humans.
Accordingly, the present invention provides, in one aspect, a compound selected from the group consisting of compounds of the formulas (I) to (IV), or as a sole stereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.

In the above formula,
Z ¹ and Z ² are independently —O—, —N (R ¹⁰ ) — or —OCH ₂ —,
R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) C (O) R ¹⁰ , or -N (H) S (O) ₂ R ¹³ ,
R ² is -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C (NH) N (H) C (O) OR ¹³ , -C (NH) N (H) C ( O) R ¹⁰ , -C- (NH) N (H) S (O) ₂ R ¹³ , or -C (NH) N (H) C (O) N (H) R ¹⁰ ,
R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C ( O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2 ) -Tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally by alkyl) Substituted),
R ⁵ is hydrogen, halo, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, alkylthio, hydroxy, mercapto, alkoxy, or —N (R ¹⁰ ) R ¹¹ ,
R ⁶ is — (C (R ⁷ ) (R ⁸ )) _n —R ⁹ (where n is 1 to 4), hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, Amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydride) Oxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl)
Wherein each R ⁷ is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, -C (O) OR ¹⁰ , -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -C- (O) -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) R ¹⁰ , -R ^12- C (O) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (OR ¹⁰ ) -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (R ¹⁰ ) (OR ¹⁰ ) C (O) OR ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -C (R ¹⁰ ) (OR ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹³ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ ,- R ¹² -N (R ¹⁰ ) S (O) ₂ R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -N (R ¹⁰ ) S (O) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -ON (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -OS (O) ₂ OR ¹⁰ , -R ¹² -P (O) (OR ¹⁰ ) R ¹¹ , -R ¹² -OP (O) ( OR ¹⁰ ) ₂ , -R ¹² -P (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -SR ¹² -C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -SR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) R ¹⁰ , -R ¹² -SSR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (0) OR ¹⁰ , -R ¹² -SC (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -SC (S) N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) R ¹⁰ , -R ¹² -S (O) ₂ R ¹³ , -R ¹² -S (O) OR ¹⁰ , -R ¹² -S (O) ₂ OR ¹⁰ , -R ¹² -S (O) ₂ N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) (NR ¹⁰ ) R ^11, or
Or each R ⁷ is aryl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N ( R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ is substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclyl (optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N ( R ¹⁰ ) R ¹¹ , -C- (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of ), Or
Or each R ⁷ is adamantyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is adamantylalkyl, wherein the adamantyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S- (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ , which is substituted with one or more substituents selected from the group consisting of ,
Each R ⁸ is independently hydrogen, alkyl, cycloalkyl, or aryl,
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ,
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), and
R ¹² is straight or branched alkylene,
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).
In another aspect, a composition useful for treating a person with a disease state characterized by thrombotic activity, comprising a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient to provide.
In another aspect, the present invention provides a method of treating a person with a disease state characterized by thrombotic activity, comprising administering to a person in need thereof a therapeutically effective amount of the compound of the present invention.
In another aspect, the present invention provides a method of treating a person with a disease state that is alleviated by inhibition of factor Xa, comprising administering to a person in need thereof a therapeutically effective amount of the compound of the present invention.
In another aspect, the invention provides a method of inhibiting human factor Xa in vitro or in vivo by administering a compound of the invention.
The invention relates to enzymes, ie purine derivatives which are useful as anticoagulants by inhibiting factor Xa, pharmaceutically acceptable salts thereof. It also relates to pharmaceutical compositions containing derivatives or pharmaceutically acceptable salts thereof, and methods of use thereof.
<Justice>
The following terms used in the specification and claims herein have the following meanings unless otherwise indicated.
"Alkyl" consists only of carbon and hydrogen and is not unsaturated and is a straight or branched monovalent or divalent radical of 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, 1-methyl Ethyl (iso-propyl), n-butyl, n-pentyl, 1,1, -dimethylethyl (t-butyl) and the like.
"Alkenyl" consists only of carbon and hydrogen, has one or more double bonds and is a straight or branched chain monovalent or divalent radical of 1 to 6 carbon atoms, for example ethenyl, prop-1 -Enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl and the like.
"Alkynyl" consists only of carbon and hydrogen, has one or more triple bonds, and is a straight or branched chain monovalent or divalent radical of 1 to 6 carbon atoms, for example ethynyl, prop -1-yl, but-1-yl, pent-1-ynyl, pent-3-ynyl and the like.
"Alkoxy" is a radical of the formula -OR _a where R _a is as defined above, for example, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, n-pentoxy, 1,1, -dimethylethoxy (t-butoxy) and the like.
“Alkoxycarbonyl” is a radical of the formula —C (O) OR _a where R _a is as defined above, for example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl , Isopropoxycarbonyl, t-butoxycarbonyl and the like.
"Alkylene" consists only of carbonyl and hydrogen and is not unsaturated and is a straight or branched chain divalent radical having 1 to 6 carbon atoms, for example methylene, ethylene, propylene, n-butylene and the like. have.
"Alkylthio" is a radical of the formula -SR _a where R _a is as defined above, for example methylthio, ethylthio, n-propylthio, t-butylthio and the like.
"Amidino" is the radical -C (NH) -NH ₂ .
"Aminocarbonyl" is a radical -C (O) NH ₂ .
"Aryl" is a phenyl or naphthyl radical.
"Aralkyl" is a radical of the formula -R _a R _b where R _a is alkyl as defined above and R _b is aryl as defined above, for example benzyl.
"Aralkoxy" is a radical of the formula -OR _c , wherein R _c is aralkyl as defined above, for example benzyloxy.
"Cycloalkyl" is a stable, 3- to 7-membered monocyclic radical, saturated, consisting only of carbon and hydrogen atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
"Cycloalkylalkyl" is an alkyl radical as defined above, substituted by a cycloalkyl radical as defined above, for example (cyclobutyl) methyl, 2- (cyclopentyl) ethyl, 3- (cyclohexyl) propyl Etc.
"Dialkylamino" is a radical of the formula -NR _a R _a where R _a is independently alkyl as defined above, for example dimethylamino, methylethylamino, diethylamino, dipropylamino, Ethylpropylamino and the like.
“Dialkylaminocarbonyl” is a radical of —C (O) NR _a R _a where Ra is independently an alkyl radical as defined above, for example dimethylaminocarbonyl, methylethylaminocarbonyl , Diethylaminocarbonyl, dipropylaminocarbonyl, ethylpropylaminocarbonyl and the like.
"Halo" is bromo, iodo, chloro or fluoro.
"Haloalkyl" is an alkyl radical as defined above substituted by one or more halo radicals as defined above, for example trifluoromethyl, difluoromethyl, trichlorobetayl, 2-trifluoroethyl , 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.
"Haloalkenyl" is an alkenyl radical as defined above substituted by one or more halo radicals as defined above, for example 2-difluoroethenyl, 3-bromo-2-fluoropropy. -1-enyl and the like.
"Haloalkoxy" is a radical of the formula -OR _f , wherein R _f is haloalkoxy as defined above, for example trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2-trifluoro Roethoxy, 1-fluoromethyl-2-fluoroethoxy, 3-bromo-2-fluoropropoxy, 1-bromomethyl-2-bromoethoxy, and the like.
"Heterocyclyl" is a 3- to 10-membered monocyclic or bicyclic radical, consisting of saturated or unsaturated, carbon atoms, and 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein nitrogen , Carbon or sulfur atoms may be optionally oxidized and nitrogen atoms may be optionally quaternized. Heterocyclyl radicals can be any hetero atom or carbon atom bonded to the main skeleton to form a stable structure. Examples of such heterocyclic radicals include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazinyl, azepinyl, pyrrolyl , 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxa Zolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolinyl, indolinyl, isoin Dodolyl, octahydroindolyl, octahydroisoindoleyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydro Furyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamor Rinil sulfoxide, thiazol-morpholinyl sulfonamido, and include, but oxadiazolyl, but is not limited to this. Preferred heterocyclic radicals in the present invention include indolyl, imidazolyl, thiazolyl, isoxazolyl, triazolyl, pyridinyl, thienyl, benzothienyl, furyl, and 3,4-dihydro-2,3 -Dioxo-1 (2H) -pyrimidinyl.
“Heterocyclylalkyl” is a radical of the formula —R _a R _g where R _a is an alkyl radical as defined above and R _g is a heterocyclyl radical as defined above, for example, Indolinylmethyl or imidazolylmethyl and the like.
"(1,2) -imidazolyl" is an imidazolyl radical bonded at the 1- or 2-position.
"(1,2) -imidazolinyl" is a 4,5-dihydroimidazolyl radical bonded at the 1- or 2-position.
"Monoalkylamino" is _a radical of the formula -NHR _a , wherein R _a is alkyl radical as defined above, for example methylamino, ethylamino, propylamino and the like.
“Monoalkylaminocarbonyl” is _a radical of the formula —C (O) NHR _a where R _a is an alkyl radical as defined above, for example methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl and the like.
"(1,2) -tetrahydropyrimidinyl" is tetrahydropyrimidinyl bonded in the 1- or 2-position.
"Adamantylalkyl" is a radical of the formula -R _a R _h where R _a is an alkyl radical as defined above and R _h is an adamantyl radical, for example adamantylmethyl, 2-adamantylethyl and the like.
"Any" or "optionally" means that the situation described below may or may not occur, including cases where such situations do and do not occur. For example, “optionally substituted aryl” may mean that an aryl radical may or may not be substituted, including both substituted aryl radicals and aryl radicals without substituents.
"Pharmaceutically acceptable salts" include both acid addition salts and base addition salts.
"Pharmaceutically acceptable acid addition salts" are salts that retain the biological efficiency and properties of the free base, and are not biologically or otherwise inappropriate, and include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, P-toluenesulfonic acid, salicylic acid It is formed using an organic acid such as.
A "pharmaceutically acceptable base addition salt" is a salt that retains the biological efficiency and properties of the free base without biologically or otherwise impairing its properties. These salts are prepared by adding an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium and magnesium salts. Salts derived from organic bases include primary, secondary and tertiary amines, substituted amines including naturally substituted amines, cyclic amines and base ion exchange resins such as isopropylamine, trimethylamine, diethyl Amine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydramine, choline , Betaine, ethylenediamine, glucosamine, methylglucamine, debromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethaneamine, dicyclohexylamine, choline and caffeine.
By "therapeutically effective amount" is meant that the amount of a compound of the invention administered to a person in need is sufficiently effective to treat a disease state characterized by thrombus activity, as defined below. The amount of a compound of the invention consisting of a “therapeutically effective amount” depends on the compound, the disease state and severity, and the age of the person to be treated, but may be routinely administered by one of ordinary skill in the art.
As used herein, "treatment"
(i) preventing a disease state occurring in a person, in particular a condition that is predisposed to a disease state but not yet diagnosed as having a disease;
(ii) inhibiting the disease state, ie inhibiting its development, or
(iii) treating a disease state characterized by thrombus activity in a human, including alleviating the disease state, ie, reducing the disease state.
The yield of each reaction described herein is expressed as a percentage of theoretical yield.
The compounds of the present invention or pharmaceutically acceptable salts thereof may have asymmetric carbon atoms in their structure. Thus, the compounds of the present invention and pharmaceutically acceptable salts thereof may exist as single stereoisomers, racemates, and mixtures of enantiomers and diastereomers. Such single stereoisomers, racemates and mixtures thereof are within the scope of the present invention.
When R ¹ is the same substituent as R ³ , R ² is the same substituent as R ^4, and Z ¹ and Z ² are the same, the compound of formula I is identical to the compound of formula II, and the compound of formula III is Same as the compound.
The compound name used herein is a modified form of the IUPAC system, wherein the compound of the present invention is named as a derivative of purine. For example, Z ¹ and Z ² are both -O-, R ¹ is -OR ¹⁰ , where R ¹⁰ is phenyl, R ² is -C (NH) NH ₂ , and R ³ is -C (O) N (R ¹⁰ ) R ¹¹ , wherein R ¹⁰ and R ¹¹ are both methyl, R ⁴ is hydrogen, R ⁵ is ethyl, and R ⁶ is-(C (R ⁷ ) (R ⁸ )) nR ⁹ where n is 1, R ⁷ is hydrogen, R ⁸ is ethyl, and R ⁹ is —C (O) OR ¹⁰ where R ¹⁰ is methyl Compounds of the invention are 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- (1-methoxycarbonylpropyl) -8-ethylpurine It is a compound of the following formula named.

<Use and administration>
A. Uses
Compounds of the invention are useful in disease states that are inhibitors of factor Xa and are characterized by thrombotic activity based on the function of factor Xa in the coagulation cascade (see background art above). The primary application of the compounds is to prevent prolonged risk after myocardial infarction. Another application is for the prevention of deep vein thrombosis (DVT) or for patients with transient ischemia after orthopedic surgery. In addition, the compounds of the present invention may be used with coumarins, such as DVT, or for other types of surgery, such as coronary artery bypass graft and percutaneous cervical angioplasty. In addition, the compound is acute promyelocytic leukemia, diabetes mellitus, multiple myeloma, disseminated intravascular coagulation due to sepsis, blunting purpura due to infection, adult respiratory distress syndrome, unstable angina, and artificial aortic valve or aortic tube related thrombus Useful for sex complications. In addition, the compounds are useful for preventing thrombotic diseases, particularly in patients at high risk of developing them.
The compounds of the invention are also useful as in vitro diagnostic reagents for selectively inhibiting factor Xa without inhibiting other components of the coagulation cascade.
B. test
The primary biological assay used to demonstrate the inhibitory effect of the compounds of the invention on factor Xa was a simple chromosome assay involving only serine proteases, i.e., compounds of the invention to be tested (e.g., Thrombosis Res. (1979). ), Vol. 16, pp. 245-254). For example, of four tissues, human serine protease, free factor Xa, prothrombinase, thrombin (IIa) and tissue plasminogen activator (tPA) can be used in the primary biological assay. Assays for TPA have previously been used successfully to demonstrate inadequate side effects in the inhibition of fibrin degradation processes (see J. Med. Chem. (1963), Vol. 36, pp.314-319). Another useful biological validation to demonstrate the utility of the compounds of the present invention in inhibiting factor Xa demonstrates the efficacy of the compounds on free factor Xa in citrated plasma. For example, the anticoagulant efficacy of a compound of the invention is tested using either prothrombin time (PT) or activated partial thromboplastin time (aPTT), while the selectivity of the compound is thrombin coagulation time (TCT). ) Confirm by analysis. The relationship of Ki to free factor Xa in the citrated plasma in the first enzyme assay will select compounds that react with or are inactivated by other plasma components. The relationship between Ki and extended PT is Efficacy in inhibition assays has been demonstrated to translate into efficacy in clinical coagulation assays. In addition, extension of PT in citrated plasma can be used to measure duration of action in subsequent pharmacokinetic studies.
For further information on assays for demonstrating the activity of the compounds of the present invention, see the following references. R. Lottenberg, Methods in Enzymology (1981), Vol. 80, pp. 341-361, H. Ohno, Thrombosis Research (1980), Vol. 19, pp. 579-588.
C. General Administration
The compounds of the present invention or pharmaceutically acceptable salts thereof may be administered in neat form or in the form of a suitable pharmaceutical composition, via an agent that serves an acceptable mode of administration or similar use. Thus, administration can be, for example, orally, intranasally, parenterally, topically, transdermally, or rectally, as a solid, semisolid, lyophilized powder, or liquid formulation, for example tablets, suppositories, Pills, soft elastic capsules and hard gelatin capsules, powders, solutions, suspensions, or aerosols, etc., may preferably consist of any suitable unit dosage form for simple administration of the correct dosage. The composition will comprise a conventional pharmaceutical carrier or excipient, and a compound of the present invention as an active agent, and may also include other agents, carriers, adjuvants, and the like.
Generally, depending on the desired mode of administration, the pharmaceutically acceptable composition comprises about 1 to 99% by weight of the compound of the present invention or a pharmaceutically acceptable salt thereof, and 1 to 99% by weight of appropriate pharmaceutical excipient. something to do. Preferably, the composition will comprise about 5 to 75% by weight of the compound of the present invention or a pharmaceutically acceptable salt thereof, and the remainder as appropriate pharmaceutical excipients.
Preferred routes of administration are oral methods using convenient daily dosing regimens, which can be adjusted according to the severity of the disease state to be treated. For such oral administration, a pharmaceutically acceptable composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof may be any of the excipients commonly used, for example pharmaceutical mannitol, lactose, starch, preparative. It is prepared by incorporating gelatinized starch, magnesium stearate, sodium saccharin, talc, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release preparations and the like.
Preferably such compositions may be in the form of capsules, caplets or tablets, and may also contain diluents such as lactose, sucrose, dicalcium phosphate; Disintegrants such as croscarmellose sodium or derivatives thereof; Lubricants such as magnesium stearate; And binders such as starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives.
In addition, the compounds of the present invention or pharmaceutically acceptable salts thereof can be dissolved slowly in vivo, such as carriers such as polyoxyethylin glycol and polyethylene glycol (PEG) such as PEG 1000 (96%) and It may be formulated as a suppository containing from about 0.5% to about 50% active ingredient in PEG 4000 (4%).
Pharmaceutically administrable liquid compositions are, for example, in a carrier (from about 0.5% to about 20%), a compound of the present invention or a pharmaceutically acceptable salt thereof, and any pharmaceutical auxiliaries such as water, saline, It can be prepared by dissolving and dispersing an aqueous dextrose solution, glycerol, ethanol and the like to form a solution or suspension.
If desired, pharmaceutical compositions of the present invention may also contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffers, antioxidants, such as citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene And the like.
Practical methods for preparing such formulations are known or will be apparent to those skilled in the art. See Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pensylvania, 1990). The composition to be administered will in any case contain a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof for treating a disease state that is alleviated by the inhibition of factor Xa in accordance with the teachings of the present invention.
Compounds of the present invention or pharmaceutically acceptable salts thereof can be used to determine the activity, metabolic stability and specific time of action of the compound to be used and the time of action of the compound, age, weight, general state of health, sex, diet, mode and time of administration, rate of release, drug Is administered in a therapeutically effective amount that can vary depending on a variety of factors including the mixed use of, the depth of the particular disease state, and the subject being treated. Generally, a therapeutically effective amount per day is from about 0.14 mg to about 14.3 mg of the compound of the present invention or a pharmaceutically acceptable salt thereof, preferably from about 0.7 mg per kg body weight per day About 10 mg, most preferably about 1.4 mg to about 7.2 mg / kg body weight per day. For example, when administered to a 70 kg individual, the dosage range is from about 10 mg to about 1.0 g per day of the compound of the invention or a pharmaceutically acceptable salt thereof, preferably about 50 mg per day To about 700 mg, most preferably about 100 mg to about 500 mg per day.
<Preferred embodiment>
Among the compounds of the present invention presented in the above summary, the preferred group is
Z ¹ and Z ² are independently —O— or —OCH ₂ —;
R ¹ and R ⁴ are each independently hydrogen, halo or -OR ¹⁰ ;
R ² is —C (NH) NH ₂ , —C (NH) N (H) S (O) ₂ R ¹³ , or —C (NH) N (H) C (O) N (H) R ¹⁰ ;
R ³ is ureido, guanidino, -C (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -N- (R ¹⁰ ) C (O ) R ¹⁰ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -already Dazolinyl (optionally substituted by alkyl);
R ⁵ is hydrogen, halo, alkyl, haloalkyl, aryl, or aralkyl;
R ⁶ is alkyl, aryl, aralkyl, or-(C (R ⁷ ) (R ⁸ )) _n -R ⁹ , where n is 1;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N ( R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ is substituted with one or more substituents selected from the group consisting of:
Or R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C- (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of )ego;
R ⁸ is independently hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
R ¹² is straight or branched alkylene;
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).
Among the groups of the above compounds, preferred compounds of the subgroups include
Z ¹ and Z ² are each -O-;
R ¹ is hydrogen or —OR ¹⁰ ;
R ² is —C (NH) NH ₂ ;
R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally by alkyl Substituted), or (1,2) -imidazolinyl (optionally substituted by alkyl);
R ⁴ is hydrogen;
R ⁵ is alkyl or aralkyl;
R ⁶ is alkyl, aralkyl, or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, hydroxy, and -OP (O) (OR ¹⁰ ) ₂ ),
Or R ⁷ is imidazolylalkyl or indolylalkyl;
R ⁸ is hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is a compound that is alkyl or aryl.
Among the compounds in the subgroups, compounds of the preferred class are
Z ¹ and Z ² are each -O-;
R ¹ is hydrogen;
R ² is —C (NH) NH ₂ ;
R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally by alkyl Substituted), or (1,2) -imidazolinyl (optionally substituted by alkyl);
R ⁴ is hydrogen;
R ⁵ is alkyl;
R ⁶ is aralkyl or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, hydroxy, and -OP (O) (OR ¹⁰ ) ₂ ),
Or R ⁷ is imidazolylalkyl or indolylalkyl;
R ⁸ is hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is a compound that is alkyl or aryl.
Among the compounds of the above classification, preferred sub-compounds are
R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -imidazolyl (optionally substituted by alkyl) or (1,2) -imidazolinyl (optionally substituted by alkyl) );
R ⁴ is hydrogen;
R ⁵ is alkyl;
R ⁶ is aralkyl or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ¹³ ;
R ⁸ is hydrogen;
R ⁹ is —C (O) OR ¹⁰ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is a compound that is alkyl or aryl.
Preferred compounds of the above subclass compounds are those in which R ³ is —C (O) N (R ¹⁰ ) R ¹¹ ; R ⁴ is hydrogen; R ⁵ is methyl or ethyl; R ⁶ is benzyl; R ¹⁰ and R ¹¹ are independently compounds which are hydrogen or methyl.
More preferred among these sub-compounds are those in which R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , wherein R ¹⁰ and R ¹¹ are both methyl, R ⁴ is hydrogen, R ⁵ is methyl, R ⁶ is benzyl, ie 2- (2-hydroxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy-8-methyl-9-benzylpurine and 6- (2 -Hydroxy-5-cyanophenoxy) -2- (3-dimethylaminocarbonyl) phenoxy-8-methyl-9-benzylpurine.
<Preparation of the compound of the present invention>
Conveniently, the following process for the preparation of the compounds of the present invention relates to the preparation of compounds of formula (I) and formula (II). However, it is understood that similar synthetic methods can be used to prepare compounds of Formula III and Formula IV. It is also understood that combinations of substituents and / or variants (eg, R ⁷ and R ⁸ ) in the compounds set forth below may be acceptable only on the assumption that such combinations result in stable compounds.
A. Preparation of Compound of Formula (IIa)
Compounds of formula (IIa) are compounds in which Z ¹ and Z ² are both -O- and R ² is -C (NH) NH ₂ . These compounds can be prepared as shown in Scheme 1, wherein R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C (O) N (R ¹⁰ ) R ¹¹ , —N (R ¹⁰ ) R ¹¹ , —N (R ¹⁰ ) C (O) R ¹⁰ , or —N (H) S (O) ₂ R ¹³ ; R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C ( O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2) Tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally substituted by alkyl) ); R ⁵ is hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, or aralkyl; R ⁶ is hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or Substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, Monoalkylaminocarbonyl, or substituted by dialkylaminocarbonyl); R ¹⁰ and R ¹¹ each independently represent hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); R ¹² is straight or branched alkylene; R ¹³ is alkyl, aryl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or di Substituted by alkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), and R ¹⁴ is alkyl.

Compounds of Formula (A), (B), (D), (G) and (K) can be purchased commercially, eg from Aldrich Chemical, Sigma Chemical, or ICN Biomedical, or prepared according to methods known to those skilled in the art. Can be.
In general, the compounds of formula (IIa) are first prepared at a temperature of from about −10 ° C. to about 10 ° C., preferably at 0 ° C., in an aprotic solvent, for example acetonitrile, Prepared by treatment with equimolar amounts of the compound of formula B in the presence. The reaction mixture was stirred at room temperature for 12-20 hours, preferably about 16 hours. The compound of formula C is then isolated from the reaction mixture using standard isolation techniques such as extraction, removal of the solvent under vacuum and flash chromatography.
Compounds of formula C in an aprotic solvent, preferably acetonitrile, at a temperature of from about −10 ° C. to about 10 ° C., preferably at 0 ° C., in equimolar amounts of the compound of formula D in the presence of a base such as cesium carbonate Treated. The resulting reaction mixture was heated to about 50 ° C. for about 3-6 hours, preferably about 4 hours. Compounds of formula E were isolated from the reaction mixture using standard techniques such as filtration, solvent removal in vacuo and flash chromatography.
Compounds of formula (E) in a protic solvent such as methanol were treated with a strong oxidizing agent such as aqueous potassium metabisulfite (KHSO ₅ ) at a temperature between about -10 ° C and about 10 ° C, preferably 0 ° C. The resulting reaction mixture was stirred at room temperature for about 12-16 hours, preferably about 15 hours. The mixture was concentrated and extracted with an aprotic solvent such as methylene chloride to afford the corresponding sulfonyl compound of formula F. The compound of formula F is dissolved in an aprotic solvent, preferably acetonitrile, at a temperature of about −10 ° C. to about 10 ° C., preferably at 0 ° C., in the presence of a base such as cesium carbonate. The compound of formula G was added to the solution and the resulting reaction mixture was stirred at room temperature for about 12 hours to about 16 hours, preferably about 16 hours. Compounds of formula H were isolated from the reaction mixture using isolation techniques such as solvent removal in vacuo and flash chromatography.
The compound of formula H was reduced under standard reducing conditions such as Zn / HCl. The resulting amino compound of formula J was isolated from the reaction mixture via standard techniques such as neutralization using a weak base such as NaHCO ₃ , then extracted using an organic solvent such as ethyl acetate, and the solvent was removed in vacuo. Polarities such as a mixture of tetrahydrofuran (THF) and ethanol at a temperature of about 60 ° C. to about 75 ° C., preferably at about 70 ° C., for about 2-4 hours, preferably about 3 hours Treated with imidate of formula K in a solvent. The compound is then heated under vacuum at about 150 ° C. to about 200 ° C., preferably at about 170 ° C., for about 1 to 3 hours, preferably about 2 hours. The reaction mixture was then concentrated to give an oil which was purified by standard purification techniques (filtration, extraction and solvent removal in vacuo) to give pure formula L.
The compound of formula L was dissolved in 0 ° C. alkanol, preferably ethanol, and the resulting solution was saturated with inorganic acid gas, preferably hydrochloric acid. The reaction mixture was sealed and warmed at room temperature for about 12 hours to about 16 hours. The reaction mixture was concentrated and a polar solvent such as ether was added to the concentrated mixture. The resulting precipitate was dissolved in alkanol, preferably ethanol, and the resulting solution was cooled to about 0 ° C. and then treated with anhydrous ammonia (gas) for about 5-20 minutes. The reaction mixture was sealed and heated at a temperature from room temperature to 100 ° C., preferably at about 60 ° C., for about 2-6 hours, preferably about 2 hours. The reaction mixture was cooled down and the solvent was evaporated. Compounds of formula (IIa) were isolated from the reaction mixture by standard isolation techniques such as filtration, evaporation of solvent and purification by preparative HPLC.
Alternatively, instead of treating the resulting solution with anhydrous ammonia, the resulting solution is treated with a compound of formula NH ₂ OR ¹⁰ to obtain a compound of formula II wherein R ² is —C (NH) N (H) OR ¹⁰ . Can be.
Compounds of formula (IIa) wherein R ³ is -C (NH) NH ₂ or -C (NH) N (H) OR ¹⁰ are produced from the corresponding cyano compounds in a similar manner as described for compounds of formula (L).
In addition, R ¹ , R ³ , R ⁴ or R ⁶ is a -C (O) N (R ¹⁰ ) R ¹¹ group or a -C (O) OR ¹⁰ group, wherein R ¹⁰ and R ¹¹ are each independently alkyl, Optionally substituted aryl or optionally substituted aralkyl) may be hydrolyzed under acidic conditions to prepare compounds of the invention wherein R ¹ , R ³ , R ⁴ or R ⁶ contain a carboxyl group. .
In addition, compounds of formula (IIa) in which R ¹ , R ³ , R ⁴ or R ⁶ comprise a —C (O) OR ¹⁰ group wherein R ¹⁰ is hydrogen, alkyl, optionally substituted aryl or optionally substituted aralkyl Is amidated under standard amidation conditions such that R ¹ , R ³ , R ⁴ or R ⁶ is a -C (O) N (R ¹⁰ ) R ¹¹ group, wherein R ¹⁰ and R ¹¹ are independently alkyl, optionally substituted Aryl or optionally substituted aralkyl).
Furthermore, a compound of formula (IIa) in which R ¹ , R ³ , R ⁴ or R ⁶ contains an amino group is treated with a suitable alkylating agent so that R ¹ , R ³ , R ⁴ or R ⁶ is -N (R ¹⁰ ) R ¹¹ or- Corresponding compounds of formula IIa can be obtained containing N (R ¹⁰ ) C (O) R ¹¹ groups, wherein R ¹⁰ and R ¹¹ are independently hydrogen, alkyl, optionally substituted aryl or optionally substituted aralkyl have.
The compound of formula (IIa) is further treated with a suitable acid halide, preferably acid chloride, or a suitable acid anhydride or equivalent so that R ² is -C (NH) N (H) C (O) R ¹⁰ , wherein R ¹⁰ is Hydrogen, alkyl, optionally substituted aryl or optionally substituted aralkyl). Alternatively, the compound of formula (IIa) may further be treated with carbamoylchloride or an equivalent thereof so that R ² is -C (NH) N (H) C (O) R ¹³ , wherein R ¹³ is described in the Summary of the Invention. And compounds of the present invention.
Alternatively, the compound of formula (IIa) is further added to a compound of formula (R ¹³ -S (O) ₂ -imidazole, wherein R ¹³ is as described in the Summary of the Invention) at room temperature in a polar solvent such as methylene chloride. Treatment gives a compound of the invention wherein R ² is —C (NH) N (H) S (O) ₂ R ¹³ .
Alternatively, the compound of formula (IIa) is further treated with an appropriate NR ¹⁰ -substituted phenylcarbamate in a polar solvent, preferably methylene chloride, at room temperature for about 6 to 24 hours, preferably about 12 hours. To obtain a compound of the invention wherein R ² is —C (NH) N (H) C (O) N (H) R ¹⁰ .
In addition, compounds of formula (IIa) wherein R ⁶ is hydrogen are described in Dusert, P. Eur. J. Med. Chem. (1980), Vol. 15, No. 3, p. 199 may be treated in a similar manner to the compounds of formula IIa wherein R ⁶ is-(C (R ⁷ ) (R ⁸ )) nR ⁹ . For example, a compound of Formula (IIa) wherein R ⁶ is hydrogen is first treated with a strong base such as sodium hydride in an aprotic solvent such as DMF, followed by equimolar amounts of Formula (C (R ⁷ ) (R ⁸ ) _n − Was treated with a compound of R ⁹ , wherein X is bromo or chloro and n, R ⁷ , R ⁸ and R ⁹ are as described in the Summary of the Invention. , Preferably for about 4 hours at room temperature to about 80 ° C. Compounds of formula IIa wherein R ⁶ is — (C (R ⁷ ) (R ⁸ ) n R ⁹ are isolated from the reaction mixture by standard isolation techniques.
Alternatively, compounds of formula IIa wherein R ⁵ is hydrogen are described in Stevenson, TM, J. Org. Chem. (1984), Vol. 49, No. 12, p. 2158 can be treated in a similar manner as described to give a compound of Formula IIa wherein R ⁵ is halo. For example, a compound of formula (IIa) in which R ⁵ is hydrogen is treated in a carbon tetrachloride with a mild electrophilic halogenating agent, for example N-bromosuccinimide or N-chlorosuccinimide, where R ⁵ is chloro or Bromo compounds of formula (IIa) can be produced.
In addition, the compounds of formula J are treated with N, N-carbonyldiimidazole or N, N-thiocarbonylimidazole under appropriate reaction conditions, in which R ⁵ is hydroxy (as carbonyl tautomer) or mercapto. Compounds of L may be formed. The compound thus formed can be treated in the same manner as described above to form a compound of formula IIa wherein R ⁵ is hydroxy or mercapto.
Compounds of formula J are also described in Omar, A. Synthesis (1977), p. 864; Ram, S., Org. Prep. Proced. Int. (1985), Vol. 17, No. 3, p. 215; Janssens, F., J. Med. Chem. (1985), Vol. 28, No. 12, p. 1925] can be treated with a thioisocyanate of the formula R ¹⁰ NCS, where R ¹⁰ is as described in the Summary of the Invention, to produce a compound of Formula L wherein R ⁵ is -N (H) R ¹⁰ . have. The compound is then treated with a standard alkylating agent, such as an alkyl halide of formula R ¹¹ X or an acid halide of formula R ¹¹ C (O) X, wherein X is halo and R ¹¹ is as described in the Summary of the Invention. R ⁵ is —NR ¹⁰ R ¹¹ , and it is possible to produce a compound of formula L wherein the nitrogen at the 5-position is thus alkylated.
Similarly, R ⁵ is meth Cobb hydantoin compound of formula IIa is of formula IIa in R ⁵ is alkylthio by treatment with alkyl halide in the same as the methyl bromide in a dipolar solvent such as dimethyl sulfoxide in the presence of a mild base such as potassium carbonate Compounds can be obtained.
Similarly, compounds of formula (IIa) wherein R ⁵ is hydroxy are further treated with alkyl halides such as methyl bromide in the presence of a strong base such as sodium hydride and an aprotic solvent such as DMF so that R ⁵ is alkoxy Can be obtained.
B. Preparation of Compound of Formula (IIa)
Compounds of formula (Ia) are compounds of formula (Ia) wherein Z ¹ and Z ² are —O— and R ² is —C (NH) NH ₂ . This compound can be prepared as shown in Scheme 2, wherein X is halo; R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ ,- N (R ¹⁰ ) C (O) R ¹⁰ , or —N (H) S (O) ₂ R ¹³ ; R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ ,- R ¹² -C (O) OR ¹⁰ , -C (O) OR ¹⁰ , -R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2) -tetrahydro Pyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally substituted by alkyl) and ; R ⁵ is hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, or aralkyl; R ⁶ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, Or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, cyano, carboxy, alkoxycarbonyl, Aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, cyano, carboxy, alkoxycarbonyl, aminocarbon Carbonyl, monoalkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, sia O, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); R ¹² is straight or branched alkylene; R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, Or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, cyano, carboxy, alkoxycarbonyl, Aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); R ¹⁴ is alkyl.

In general, compounds of formula (Ia) can be treated with compounds of formula (G) by treating compounds of formula (A) with compounds of formula (G) in a similar manner as described for preparing compounds of formula (H) from formulas (F) and (G). The compound of formula M can then be treated with a compound of formula D by a method analogous to the method described above for the compound of formula C. The compound of formula N is then oxidized to the corresponding compound of formula O in a manner analogous to the method described for the compound of formula E. Compounds of formula (O) are treated with compounds of formula (B) in a similar manner to those described for compounds of formula (A) to obtain compounds of formula (P), which are corresponding to compounds of formula (Q) Reduced to. The compound of formula Q is then treated with alkyl imide of formula K in a similar manner to that described for compound of formula J to obtain a compound of formula R, which is similar to the method described for compound of formula L Convert to the corresponding amidine derivative of.
In addition, all of the various substituent conversions described for compounds of Formula (IIa) are applied to compounds of Formula (Ia) to obtain additional compounds of the invention that are not shown in the above scheme.
Similar reactions can also be carried out on similar starting materials and intermediates to form the corresponding compounds of formula III and compounds of formula IV.
In addition, all compounds of the present invention in free base form or free acid form may be converted into pharmaceutically acceptable salts by treatment with an appropriate inorganic or organic acid, or with an appropriate inorganic or organic base. In addition, salts of the compounds of the present invention can be converted into the free base form or the free acid form or other salts by methods known to those skilled in the chemical arts.
The following specific preparations and examples are provided as a guide for carrying out the invention and are not intended to limit the scope of the invention.
<Production example 1>
Compounds of formulas C and P
A. 5.0 g (20.8 mmol) of 4,6-dichloro-5-nitro-2-methylthiopyrimidine in 200 ml of acetonitrile at 0 ° C., 8.82 g (27.1 mmol) of cesium carbonate, followed by 3-hydroxy-4 4.69 g (20.8 mmol) benzyloxybenzonitrile were added and the resulting reaction mixture was stirred for 16 h. The volatiles were evaporated and the residue was chromatographed on silica gel (hexane / ethyl acetate, 2: 1) to 2-methylthio-4-chloro-5-nitro-6- (2-benzyloxy-5-cyanophenoxy Pyrimidine, i.e., 5.0 g of the compound of formula C was obtained.
B. In a similar manner, compounds of formula C were prepared.
2-methylthio-4-chloro-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine, and
2-methylthio-4-chloro-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine,
C. In a similar manner, 2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine is reacted with 3-hydroxy-4-benzyloxy in the presence of cesium carbonate. Treatment with benzonitrile 2- (2-benzyloxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine, ie a compound of formula P Got.
D. A compound of formula P was prepared in a similar manner.
2- (2-benzyloxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-methoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-ethoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-phenoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-chloro-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-methyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-t-butyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-nitro-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-carboxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-amino-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-benzyloxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3- (1-methylimidazolin-2-yl) -phenoxy) pyrimidine,
2- (2-methoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3- (2- (t-butoxycarbonyl) ethyl) -phenoxy) pyrimidine,
2- (2-ethoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-t-butoxycarbonyl-phenoxy) pyrimidine,
2- (2-phenoxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-carboxyphenoxy) pyrimidine,
2- (2-chloro-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3- (2-aminoethyl) phenoxy) pyrimidine,
2- (2-methyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3- (benzyloxy) phenoxy) pyrimidine,
2- (2-t-butyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-ethoxyphenoxy) pyrimidine,
2- (2-nitro-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-guanidinophenoxy) pyrimidine,
2- (2-carboxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-ureidophenoxy) pyrimidine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-aminophenoxy) pyrimidine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-nitrophenoxy) pyrimidine, and
2- (2-amino-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-trifluoromethoxyphenoxy) pyrimidine.
<Production example 2>
Compound of Formula E and Formula N
A. Cesium carbonate in 2.5 g (5.83 mmol) of 6- (2-benzyloxy-5-cyanophenoxy) -4-chloro-5-nitro-2-methylthiopyrimidine in 50 ml of acetonitrile at 0 ° C. 2.47 g (7.58 mmol), then 0.64 mL of benzylamine were added and the reaction mixture was heated at 50 ° C. for 4 h. The reaction was filtered, the filtrate was evaporated and the residue was chromatographed on silica gel (ethylacetate: hexane) to give 6- (2-benzyloxy-5-cyanophenoxy) -4- (benzyl) amino-5-nitro- 2-methylthiopyrimidine, that is, 1.82 g (65%) of the compound of formula E was obtained.
B. In a similar manner, compounds of formula E were prepared.
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine,
2-methylthio-4- (benzyl) amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2-methylthio-4-amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine, and
2-methylthio-4-amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine.
C. In a similar manner, 3.19 g of 2-methylthio-4-chloro-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine in 90 mL of acetonitrile at 0 ° C., i. (8.65 mmol) to 3.66 g (11.2 mmol) cesium carbonate followed by 0.95 mL (8.65 mmol) of benzylamine. The reaction mixture was heated at 75 ° C. for 4 hours. The reaction was filtered, the filtrate was evaporated and the residue was chromatographed on silica gel (ethylacetate: methanol, 10: 1) to give 2-methylthio-4- (benzyl) amino-5-nitro-6- (3-dimethylamino Carbonylphenoxy) pyrimidine, i.e., 1.76 g (48%) of compound of formula (N) was obtained.
D. In a similar manner, compounds of formula N were prepared.
2-methylthio-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) phenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-methoxyphenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-chlorophenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-chloro-5-methoxyphenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-trifluoromethyl-5- (dimethylaminocarbonyl) phenoxypyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-guanidinophenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-ureidophenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-nitrophenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-guanidino-5-methylphenoxy) pyrimidine,
2-methylthio-4-benzylamino-5-nitro-6- (3-ureido-5-methylphenoxy) pyrimidine, and
2-methylthio-4-benzylamino-5-nitro-6- (3-nitro-5-aminophenoxy) pyrimidine.
<Production example 3>
Compounds of formulas F and O
A. 1.82 g (3.76 mmol) of 2-methylthio-4-benzylamino-5-nitro-6- (2-benzyloxy-5-cyanophenoxy) pyrimidine in 40 mL of MeOH and 40 mL of dioxane at 0 ° C. ) Was added 3.59 g (11.3 mmol) of potassium metabisulfite (KHSO5) in 40 mL of water. The suspension was warmed up to room temperature and stirred for 15 hours. The reaction was concentrated to 25 mL and extracted with 200 mL methylene chloride. The organic layer was dried over sodium sulfate, evaporated and chromatographed on silica gel (2: 1 hexanes / ethyl acetate) to 2-methylsulfonyl-4-benzylamino-5-nitro-6- (2-benzyloxy-5-sia Nophenoxy) pyrimidine, i.e. 0.26 g of compound of Formula F, was obtained as a white solid.
B. In a similar manner, compounds of formula F were prepared.
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4- (benzyl) amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2-methylsulfonyl-4-amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine, and
2-methylsulfonyl-4-amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine.
C. In a similar manner, 2-methylthio-4-benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine, ie the compound of formula N, is oxidized to yield 2-methylsulfonyl-4 -Benzylamino-5-nitro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine, ie a compound of formula (O).
D. In a similar manner, compounds of formula (O) were prepared.
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) phenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-methoxyphenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-chlorophenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-chloro-5-methoxyphenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-trifluoromethyl-5- (dimethylaminocarbonyl) phenoxypyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-guanidinophenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-ureidophenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-nitrophenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-guanidino-5-methylphenoxy) pyrimidine,
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-ureido-5-methylphenoxy) pyrimidine, and
2-methylsulfonyl-4-benzylamino-5-nitro-6- (3-nitro-5-aminophenoxy) pyrimidine.
<Production example 4>
Compounds of formulas H and M
A. 2-methylsulfonyl-4-benzylamino-5-nitro-6- (2-benzyloxy-5-cyanophenoxy) pyrimidine in 15 ml of acetonitrile at 0 ° C., 0.69 g of compound of formula F To (1.38 mmol) cesium carbonate was added followed by 0.20 g (1.24 mmol) of 3- (dimethylaminocarbonyl) phenol and the reaction was stirred for 16 hours. The volatiles were evaporated and the residue was chromatographed on silica gel (7: 2 CH ₂ Cl ₂ / ethyl acetate) to give 2- (3-dimethyl-aminocarbonylphenoxy) -4-benzylamino-5-nitro-6- 0.22-g of (2-benzyloxy-5-cyanophenoxy) pyrimidine, the compound of formula H, was obtained.
B. In a similar manner, compounds of formula H were prepared.
2- (3-methylphenoxy) -4- (benzyl) amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2- (3-chloro-5-methoxyphenoxy) -4- (benzyl) amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2- (4-trifluoromethylphenoxy) -4- (benzyl) amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2- (3,5-dinitrophenoxy) -4- (benzyl) amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3-guanidino-5-methylphenoxy) -4- (benzyl) amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-ureidophenoxy) -4- (benzyl) amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3- (2-chloroethyl) -5-methylphenoxy) -4- (benzyl) amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4- (benzyl) amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2- (4-ethoxycarbonylphenoxy) -4- (benzyl) amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazol-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminophenoxy) -4- (benzyl) amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2- (3-t-butoxycarbonylphenoxy) -4- (benzyl) amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy Pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy Pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine ,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine ,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4-amino-5-nitro-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4-amino-5-nitro-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4-amino-5-nitro-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4-amino-5-nitro-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4-amino-5-nitro-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (2-nitro-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4-amino-5-nitro-6- (3-nitro-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (3-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine, and
2- (3-guanidinophenoxy) -4-amino-5-nitro-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine.
C. In a similar manner, 2-methylthio-5-nitro-4,6-dichloropyrimidine is treated with 3- (dimethylaminocarbonyl) phenol in the presence of cesium carbonate to give 2-methylthio-5-nitro-4 -Chloro-6- (3-dimethylaminocarbonylphenoxy) pyrimidine, i.e. a compound of formula (M), was obtained.
D. In a similar manner, compounds of formula M were prepared.
2-methylthio-4-chloro-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) phenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-methoxyphenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3- (2-dimethylaminocarbonyl) ethyl) -5-chlorophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-chloro-5-methoxyphenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-trifluoromethyl-5- (dimethylaminocarbonyl) phenoxypyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-guanidinophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-ureidophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-nitrophenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-guanidino-5-methylphenoxy) pyrimidine,
2-methylthio-4-chloro-5-nitro-6- (3-ureido-5-methylphenoxy) pyrimidine, and
2-methylthio-4-chloro-5-nitro-6- (3-nitro-5-aminophenoxy) pyrimidine.
<Production example 5>
Compounds of Formula J and Q
A. 0.29 g of 2- (3-dimethylaminocarbonylphenoxy) -4-benzylamino-5-nitro-6- (2-benzyloxy-5-cyanophenoxy) pyrimidine, i.e. 0.47 mmol) and 0.1 g of granulated zinc were mixed with 10 ml of THF and 1.0 ml of 10% HCl aqueous solution. The reaction was heated at 80 ° C for 90 minutes. The volatiles were evaporated. Saturated aqueous NaHCO ₃ solution was added, and the solution was extracted with 300 mL of ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to 2- (3-dimethylaminocarbonylphenoxy) -4-benzylamino-5-amino-6- (2-benzyloxy-5-cyanophenoxy) pyrimidine, That is, 0.27 g of a compound of formula J was obtained.
B. In a similar manner, compounds of formula J were prepared.
2- (3-methylphenoxy) -4- (benzyl) amino-5-amino-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2- (3-chloro-5-methoxyphenoxy) -4- (benzyl) amino-5-amino-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2- (4-trifluoromethylphenoxy) -4- (benzyl) amino-5-amino-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2- (3,5-diaminophenoxy) -4- (benzyl) amino-5-amino-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3-guanidino-5-methylphenoxy) -4- (benzyl) amino-5-amino-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-ureidophenoxy) -4- (benzyl) amino-5-amino-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3- (2-chloroethyl) -5-methylphenoxy) -4- (benzyl) amino-5-amino-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4- (benzyl) amino-5-amino-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2- (4-ethoxycarbonylphenoxy) -4- (benzyl) amino-5-amino-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazol-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (2-methyl-4-cyanophenoxy) pyrimidine,
2- (3-dimethylaminophenoxy) -4- (benzyl) amino-5-amino-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy-4- (benzyl) amino-5-amino-6- (2-amino-5-cyanophenoxy) pyrimidine,
2- (3-t-butoxycarbonylphenoxy) -4- (benzyl) amino-5-amino-6- (3-amino-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (2-t-butoxycarbonyl-5-cyanophenoxy Pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (3-t-butoxycarbonyl-4-cyanophenoxy Pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine ,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine ,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4,5-diamino-6- (2-methoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4,5-diamino-6- (2-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4,5-diamino-6- (3-methoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4,5-diamino-6- (3-ethoxy-5-cyanophenoxy) pyrimidine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -4,5-diamino-6- (2-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (3-phenoxy-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (2-chloro-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (3-bromo-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (2-methyl-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (3-methyl-4-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (2-amino-5-cyanophenoxy) pyrimidine,
2- (3-dimethylaminocarbonylphenoxy) -4,5-diamino-6- (3-amino-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (2-carboxy-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (3-carboxy-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (2-t-butoxycarbonyl-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (2-t-butoxycarbonyl-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (2-aminocarbonyl-5-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (3-aminocarbonyl-4-cyanophenoxy) pyrimidine,
2- (3-guanidinophenoxy) -4,5-diamino-6- (2-dimethylamino-5-cyanophenoxy) pyrimidine, and
2- (3-guanidinophenoxy) -4,5-diamino-6- (3-dimethylamino-4-cyanophenoxy) pyrimidine.
C. In a similar manner, 2- (2-benzyloxy-5-cyanophenoxy) -4-benzylamino-5-nitro-6- (3-dimethylaminocarbonyl) phenoxypyrimidine, ie of formula P Reducing 1.2 g (1.95 mmol) of the compound to yield 2- (2-benzyloxy-5-cyanophenoxy) -4-benzylamino-5-amino-6- (3-dimethylaminocarbonyl) phenoxypyrimidine, In other words, a compound of formula Q was obtained.
D. In a similar manner, compounds of formula Q were prepared.
2- (2-benzyloxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-methoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-ethoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-phenoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-chloro-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-methyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-t-butyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-amino-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-carboxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-amino-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonylphenoxy) pyrimidine,
2- (2-benzyloxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3- (1-methylimidazolin-2-yl) -phenoxy) pyrimidine ,
2- (2-methoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) pyrimidine ,
2- (2-ethoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-t-butoxycarbonylphenoxy) pyrimidine,
2- (2-phenoxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-carboxyphenoxy) pyrimidine,
2- (2-chloro-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3- (2-aminoethyl))-phenoxy) pyrimidine,
2- (2-methyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3- (benzyloxy) -phenoxy) pyrimidine,
2- (2-t-butyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-ethoxyphenoxy) pyrimidine,
2- (2-amino-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-guanidinophenoxy) pyrimidine,
2- (2-carboxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-ureidophenoxy) pyrimidine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-aminophenoxy) pyrimidine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-aminophenoxy) pyrimidine, and
2- (2-amino-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-trifluoromethoxyphenoxy) pyrimidine.
<Production example 6>
Compounds of Formulas L and R
A. 2- (3-dimethylaminocarbonylphenoxy) -4- (benzyl) amino-5-amino-6- (2-benzyloxy-5-cyanophenoxy) pyrimidine, ie compound 0.26 g (0.44 mmol) was treated with 0.17 g (1.3 mmol) ethyl imidate hydrochloride in THF / ethanol at 80 ° C. for 6 hours and then concentrated to an oil. The residue was heated in a sand bath at 170 ° C. under vacuum for 2.0 h, cooled, filtered through a pad of silica and eluted with 5% methanol in methylenechloride. The volatiles were evaporated to yield 2- (3-dimethylaminocarbonylphenoxy) -6- (2-benzyloxy-5-cyanophenoxy) -8-methyl-9-benzylpurine, i.e. 0.20 g of a compound of formula L Got.
B. In a similar manner, compounds of formula L were prepared.
2- (3-methylphenoxy) -6- (2-methoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-chloro-5-methoxyphenoxy) -6- (2-ethoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (4-trifluoromethylphenoxy) -6- (3-methoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3,5-diaminophenoxy) -6- (3-ethoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-guanidino-5-methylphenoxy) -6- (2-phenoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-ureidophenoxy) -6- (3-phenoxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (2-chloroethyl) -5-methylphenoxy) -6- (2-chloro-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (4-ethoxycarbonylphenoxy) -6- (2-methyl-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazol-2-yl) phenoxy) -6- (2-methyl-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-dimethylaminophenoxy) -6- (3-methyl-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-amino-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3-t-butoxycarbonylphenoxy) -6- (3-amino-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-carboxy-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-carboxy-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-t-butoxycarbonyl-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-t-butoxycarbonyl-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-aminocarbonyl-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-aminocarbonyl-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-dimethylamino-5-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-dimethylamino-4-cyanophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-methoxy-5-cyanophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-ethoxy-5-cyanophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-methoxy-5-cyanophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-ethoxy-5-cyanophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-phenoxy-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-phenoxy-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-chloro-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-methyl-4-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-amino-5-cyanophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-amino-4-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-carboxy-5-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-carboxy-4-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-t-butoxycarbonyl-5-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-t-butoxycarbonyl-4-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-aminocarbonyl-5-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-aminocarbonyl-4-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-dimethylamino-5-cyanophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-dimethylamino-4-cyanophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-methoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-ethoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-methoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-ethoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-phenoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-phenoxy-5-cyanophenoxy) -8-ethylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-chloro-5-cyanophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-cyanophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-cyanophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-cyanophenoxy) -8-phenylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-methyl-4-cyanophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-amino-5-cyanophenoxy) -8-phenylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-amino-4-cyanophenoxy) -8-phenylpurine,
2- (3-guanidinophenoxy) -6- (2-carboxy-5-cyanophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (3-carboxy-4-cyanophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (2-t-butoxycarbonyl-5-cyanophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (3-t-butoxycarbonyl-4-cyanophenoxy) -8-trifluoromethylpurine,
2- (3-guanidinophenoxy) -6- (2-aminocarbonyl-5-cyanophenoxy) -8-trifluoromethylpurine, and
2- (3-guanidinophenoxy) -6- (3-aminocarbonyl-4-cyanophenoxy) -8-ethylpurine. And
2- (3-guanidinophenoxy) -6- (2-dimethylamino-5-cyanophenoxy) -8-ethylpurine.
C. In a similar manner, 1.14 g of 2- (2-benzyloxy-5-cyanophenoxy) -4- (benzyl) amino-5-amino-6- (3-dimethylaminocarbonyl) phenoxypyrimidine ( 1.94 mmol) was treated with 0.31 g (2.53 mmol) of ethylimidate hydrochloride to treat 2- (2-benzyloxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy-8-methyl 0.39 g (2.53 mmol) of -9-benzylpurine, i.e.
D. In a similar manner, compounds of formula R
2- (2-benzyloxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-methoxy-5-cyanophenoxy)-(3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-ethoxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-phenoxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-chloro-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-methyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy-8-methyl-9-benzylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-benzyloxy-5-cyanophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-methyl-9-benzylpurine,
2- (2-methoxy-5-cyanophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methyl-9-benzylpurine,
2- (2-ethoxy-5-cyanophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-phenoxy-5-cyanophenoxy) -6- (3-carboxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-chloro-5-cyanophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-methyl-9-benzylpurine,
2- (2-methyl-5-cyanophenoxy) -6- (3- (benzyloxy) -phenoxy) -8-methyl-9-benzylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-ethoxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-guanidinophenoxy) -8-methyl-9-benzylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-ureidophenoxy) -8-methyl-9-benzylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-methyl-9-benzylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-methyl-9-benzylpurine.
2- (2-benzyloxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-methoxy-5-cyanophenoxy)-(3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-ethoxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-phenoxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-chloro-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-methyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy-8-methylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-benzyloxy-5-cyanophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-methylpurine,
2- (2-methoxy-5-cyanophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methylpurine,
2- (2-ethoxy-5-cyanophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methylpurine,
2- (2-phenoxy-5-cyanophenoxy) -6- (3-carboxyphenoxy) -8-methylpurine,
2- (2-chloro-5-cyanophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-methylpurine,
2- (2-methyl-5-cyanophenoxy) -6- (3- (benzyloxy) -phenoxy) -8-methylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-ethoxyphenoxy) -8-methylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-guanidinophenoxy) -8-methylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-ureidophenoxy) -8-methylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-methylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-methylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-ethylpurine.
2- (2-methyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy-8-ethylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethyl-9-ethylpurine,
2- (2-benzyloxy-5-cyanophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-ethyl-9-ethylpurine,
2- (2-methoxy-5-cyanophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-ethyl-9-ethylpurine,
2- (2-ethoxy-5-cyanophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-ethyl-9-ethylpurine,
2- (2-phenoxy-5-cyanophenoxy) -6- (3-carboxyphenoxy) -8-ethyl-9-ethylpurine,
2- (2-chloro-5-cyanophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-ethyl-9-ethylpurine,
2- (2-methyl-5-cyanophenoxy) -6- (3- (benzyloxy) -phenoxy) -8-ethyl-9-ethylpurine,
2- (2-t-butyl-5-cyanophenoxy) -6- (3-ethoxyphenoxy) -8-ethyl-9-ethylpurine,
2- (2-amino-5-cyanophenoxy) -6- (3-guanidinophenoxy) -8-ethyl-9-ethylpurine,
2- (2-carboxy-5-cyanophenoxy) -6- (3-ureidophenoxy) -8-ethyl-9-ethylpurine,
2- (2-benzyloxycarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-ethyl-9-ethylpurine,
2- (2-diethylaminocarbonyl-5-cyanophenoxy) -6- (3-aminophenoxy) -8-ethyl-9-ethylpurine, and
2- (2-amino-5-cyanophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-ethyl-9-ethylpurine.
<Example 1>
Compounds of Formulas I and II
A. 0.2 g (0.33 mmol) of 6- (2-benzyloxy-5-cyanophenoxy) -2- (3-dimethylaminocarbonyl) phenoxy-8-methyl-9-benzylpurine at 0 ° C. In a vessel was dissolved in 5.0 ml of ethanol and saturated with HCl gas. The reaction was sealed and allowed to warm to room temperature for 16 hours. The reaction mixture was then concentrated to 20 mL and ether was added. The resulting precipitate was dissolved in 30 ml of ethanol, cooled to 0 ° C. and ammonia gas was bubbled through the solution for 10 minutes. The reaction was sealed and heated at 60 ° C. for 2 hours. The reaction mixture was cooled, the tube was opened carefully and the volatiles were evaporated to give 0.152 g of crude product. Purification by preparative HPLC gave 6- (2-hydroxy-5-amidinophenoxy) -2- (3-dimethylaminocarbonyl) phenoxy-8-methyl-9-benzylpurine, i.e. compound of formula II 0.015 g was obtained. NMR (DMSOd6) 9.10 (brs, 2), 8.80 (brs, 2), 7.80 (d, 1), 7.70 (d, 1), 7.10-7.50 (m, 10), 5.40 (s, 2), 3.00 (brs, 6), 2.70 (s, 2).
B. In a similar manner, compounds of formula II were prepared.
2- (3-methylphenoxy) -6- (2-methoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-chloro-5-methoxyphenoxy) -6- (2-ethoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (4-trifluoromethylphenoxy) -6- (3-methoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3,5-diaminophenoxy) -6- (3-ethoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-guanidino-5-methylphenoxy) -6- (2-phenoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-ureidophenoxy) -6- (3-phenoxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (2-chloroethyl) -5-methylphenoxy) -6- (2-chloro-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (4-ethoxycarbonylphenoxy) -6- (2-methyl-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazol-2-yl) phenoxy) -6- (2-methyl-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-dimethylaminophenoxy) -6- (3-methyl-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-amino-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3-t-butoxycarbonylphenoxy) -6- (3-amino-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-carboxy-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-carboxy-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-t-butoxycarbonyl-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-t-butoxycarbonyl-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-aminocarbonyl-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-aminocarbonyl-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-dimethylamino-5-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-dimethylamino-4-amidinophenoxy) -8-methyl-9-benzylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-methoxy-5-amidinophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-ethoxy-5-amidinophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-methoxy-5-amidinophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-ethoxy-5-amidinophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-phenoxy-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-phenoxy-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-chloro-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-methyl-4-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-amino-5-amidinophenoxy) -8-methylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-amino-4-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-carboxy-5-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-carboxy-4-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-t-butoxycarbonyl-5-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-t-butoxycarbonyl-4-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-aminocarbonyl-5-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (3-aminocarbonyl-4-amidinophenoxy) -8-methylpurine,
2- (3-guanidinophenoxy) -6- (2-dimethylamino-5-amidinophenoxy) -8-methylpurine, and
2- (3-guanidinophenoxy) -6- (3-dimethylamino-4-amidinophenoxy) -8-methylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-methoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-ethoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-methoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (3-ethoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3- (1-methylimidazolin-2-yl) phenoxy) -6- (2-phenoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-phenoxy-5-amidinophenoxy) -8-ethylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-chloro-5-amidinophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-bromo-5-amidinophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-amidinophenoxy) -8-benzylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-methyl-5-amidinophenoxy) -8-phenylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-methyl-4-amidinophenoxy) -8-phenylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (2-amino-5-amidinophenoxy) -8-phenylpurine,
2- (3-dimethylaminocarbonylphenoxy) -6- (3-amino-5-amidinophenoxy) -8-phenylpurine,
2- (3-guanidinophenoxy) -6- (2-carboxy-5-amidinophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (3-carboxy-4-amidinophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (2-t-butoxycarbonyl-5-amidinophenoxy) -8-t-butylpurine,
2- (3-guanidinophenoxy) -6- (3-t-butoxycarbonyl-4-amidinophenoxy) -8-trifluoromethylpurine,
2- (3-guanidinophenoxy) -6- (2-aminocarbonyl-5-amidinophenoxy) -8-trifluoromethylpurine,
2- (3-guanidinophenoxy) -6- (3-aminocarbonyl-4-amidinophenoxy) -8-ethylpurine,
2- (3-guanidinophenoxy) -6- (2-dimethylamino-5-amidinophenoxy) -8-ethylpurine, and
2- (3-guanidinophenoxy) -6- (3-dimethylamino-4-amidinophenoxy) -8-ethylpurine.
C. In a similar manner, add 0.65 g of 2- (2-benzyloxy-5-cyanophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy-8-methyl-9-benzylpurine in 2- (2 -Hydroxy-5-aminophenoxy) -6- (3-dimethylaminocarbonyl) -phenoxy-8-methyl-9-benzylpurine, ie 0.39 g of a compound of formula (I). NMR (DMSOd6) 9.10 (brs, 2), 8.80 (brs, 2), 7.70 (d, 1), 7.65 (d, 1), 7.50 (dd, 1), 7.25-7.40 (m, 8), 7.10 (d, 1), 5.40 (s, 2), 3.00 (s, 3), 2.90 (s, 3), 2.70 (s, 3).
D. In a similar manner, compounds of formula (I)
2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-methoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-chloro-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-methyl-9-benzylpurine,
2- (2-methoxy-5-amidinophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methyl-9-benzylpurine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methyl-9-benzylpurine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-chloro-5-amidinophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-methyl-9-benzylpurine,
2- (2-methyl-5-amidinophenoxy) -6- (3-hydroxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-ethoxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-guanidinophenoxy) -8-methyl-9-benzylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-ureidophenoxy) -8-methyl-9-benzylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-methyl-9-benzylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-methyl-9-benzylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-methyl-9-benzylpurine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-methoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-chloro-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methylpurine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-methylpurine,
2- (2-methoxy-5-amidinophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methylpurine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methylpurine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-methylpurine,
2- (2-chloro-5-amidinophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-methylpurine,
2- (2-methyl-5-amidinophenoxy) -6- (3-hydroxyphenoxy) -8-methylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-ethoxyphenoxy) -8-methylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-guanidinophenoxy) -8-methylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-ureidophenoxy) -8-methylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-methylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-methylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-ethylpurine.
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-ethyl-9-ethylpurine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3- (1-methylimidazolin-2-yl) -phenoxy) -8-ethyl-9-ethylpurine,
2- (2-methoxy-5-amidinophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-ethyl-9-ethylpurine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-ethyl-9-ethylpurine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-ethyl-9-ethylpurine,
2- (2-chloro-5-amidinophenoxy) -6- (3- (2-aminoethyl))-phenoxy) -8-ethyl-9-ethylpurine,
2- (2-methyl-5-amidinophenoxy) -6- (3-hydroxyphenoxy) -8-ethyl-9-ethylpurine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-ethoxyphenoxy) -8-ethyl-9-ethylpurine,
2- (2-amino-5-amidinophenoxy) -6- (3-guanidinophenoxy) -8-ethyl-9-ethylpurine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-ureidophenoxy) -8-ethyl-9-ethylpurine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-ethyl-9-ethylpurine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-aminophenoxy) -8-ethyl-9-ethylpurine, and
2- (2-amino-5-amidinophenoxy) -6- (3-trifluoromethoxyphenoxy) -8-ethyl-9-ethylpurine.
E. Compounds of formula (I) and formula (II) wherein R ⁵ prepared above are hydrogen are described in Dusert, P., Eur. J. Med. Chem. (1980), Vol. 3, p199 can be further treated in a similar manner to the method described in the following to produce the following compound.
2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxyethyl) purine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-ethoxycarbonylethyl) purine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-aminocarbonylethyl) purine,
2- (2-methoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2-methylpropyl) purine,
2- (2-methoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-ethoxycarbonyl) -2-methylpropyl) purine ,
2- (2-methoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-aminocarbonyl) -2-methylpropyl) purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-3-methylbutyl) purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -3-methylbutyl) Purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -3-methylbutyl) purine ,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2-methylbutyl) purine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2-methylbutyl) Purine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2-methylbutyl) purine ,
2- (2-chloro-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2-phenylethyl) purine,
2- (2-chloro-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2-phenylethyl) purine ,
2- (2-chloro-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2-phenylethyl) purine,
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2- (4-mercaptophenyl) ethyl) Purine,
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2- (4-mer Captophenyl) ethyl) purine,
2- (2-methyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2- (4-mercapto Phenyl) ethyl) purine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2- (indolin-3-yl ) Ethyl) purine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2- (indole Lin-3-yl) ethyl) purine,
2- (2-t-butyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2- (indolin -3-yl) ethyl) purine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2- (imidazol-4-yl) ethyl Purine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2- (imidazole- 4-yl) ethyl) purine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2- (imidazole-4 -Yl) ethyl) purine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2-hydroxyethyl) purine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2-hydroxyethyl) Purine,
2- (2-carboxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2-hydroxyethyl) purine ,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2-hydroxypropyl) purine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2-hydride Oxypropyl) purine,
2- (2-benzyloxycarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -2-hydroxy Profile) Purine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1-carboxy-2- (aminocarbonyl) Ethyl) purine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -2- (Aminocarbonyl) ethyl) purine,
2- (2-diethylaminocarbonyl-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9- (1,2-di (aminocarbonyl) ethyl Purine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy) -8-methyl-9- (1-carboxy-3- (aminocarbonyl) propyl) purine ,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -3- (aminocarbon Carbonyl) propyl) purine,
2- (2-amino-5-amidinophenoxy) -6- (3-dimethylaminocarbonyl) phenoxy) -8-methyl-9- (1,3-di (aminocarbonyl) propyl) purine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3- (1-methylimidazolin-2-yl) phenoxy) -8-methyl-9- (1,2-dicarboxy Ethyl) purine,
2- (2-hydroxy-5-amidinophenoxy) -6- (3- (1-methylimidazolin-2-yl) phenoxy) -8-methyl-9- (1,2-di ( Ethoxycarbonyl) ethyl) purine,
2- (2-methoxy-5-amidinophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methyl-9- (1,3-di Carboxypropyl) purine,
2- (2-methoxy-5-amidinophenoxy) -6- (3- (2- (t-butoxycarbonyl) ethyl) phenoxy) -8-methyl-9- (1,3-di (Ethoxycarbonyl) propyl) purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3- (t-butoxycarbonylphenoxy) -8-methyl-9- (1-carboxy-5-aminopentyl) purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -5-aminophen Till) Purine,
2- (2-ethoxy-5-amidinophenoxy) -6- (3-t-butoxycarbonylphenoxy) -8-methyl-9- (1- (aminocarbonyl) -5-aminopentyl Purine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-methyl-9- (1-carboxy-4-guanidinobutyl) purine,
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-methyl-9- (1- (ethoxycarbonyl) -4-guanidinobutyl) purine , And
2- (2-phenoxy-5-amidinophenoxy) -6- (3-carboxyphenoxy) -8-methyl-9- (1- (aminocarbonyl) -4-guanidinobutyl) purine.
<Example 2>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-hydroxy-4-amidinophenoxy) -9- ( Described is a method for preparing a representative pharmaceutical composition for oral administration comprising 1-methoxycarbonyl-propyl) -8-methyl-9-benzylpurine.
A. Component weight / wt%
Compound of the Invention 20.0%
Lactose 79.5%
Magnesium Stearate0.5%
The ingredients are mixed and dispensed into hard gelatin capsules of 100 mg each.
B. Ingredient Weight / Weight%
Compound of the Invention 20.0%
Magnesium Stearate0.9%
Starch 8.6%
Lactose 79.6%
Polyvinylpyrrolidone (PVP) 0.9%
The above ingredients except magnesium stearate are mixed and granulated using water as granulating agent. The formulation is then dried and mixed with magnesium stearate to form tablets with a suitable tablet machine.
C. Ingredients
Compound of the Invention0.1 g
Propylene Glycol20.0 g
Polyethylene glycol 40020.0 g
801.0 g of polysorbates
Water amount 100 ml
The present invention dissolves the compound in propylene glycol, polyethylene glycol 400 and polysorbate 80. Sufficient water is added with stirring to make 100 ml of the filtered and bottled solution.
D. Ingredient weight / wt%
Compound of the Invention 20.0%
Peanut oil78.0%
Span 60 2.0%
In the present invention, the compound is melted, mixed, and filled into a soft elastic capsule.
E. Component Weight / Weight%
Compound of the Invention 1.0%
Methyl or carboxymethyl cellulose 2.0%
0.9 ml of saline solution 100 ml
Compounds of the invention were dissolved in cellulose / saline solution, filtered and bottled for use.
<Example 3>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- ( Described are methods for preparing representative pharmaceutical compositions for parenteral administration, including 1-methoxycarbonylpropyl) -8-methylpurine.
ingredient
Compound of the Invention0.02 g
Propylene Glycol20.0 g
Polyethylene glycol 40020.0 g
801.0 g of polysorbates
0.9 ml of saline solution 100 ml
The present invention dissolves the compound in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient amount of 0.9% brine is added with stirring to filter through a 0.2 μm membrane filter under sterile conditions and to 100 ml of the filled solution.
<Example 4>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- ( Described are methods for preparing representative pharmaceutical compositions in suppository form comprising 1-methoxycarbonylpropyl) -8-ethyl-9-benzylpurine.
Ingredient weight / weight%
Compound of the Invention 1.0%
Propylene Glycol 100074.5%
Polyethylene Glycol 40024.5%
The components were melted and mixed in a steam bath and placed in a mold with a total weight of 2.5 g.
<Example 5>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- ( Described is a method for preparing a representative pharmaceutical composition for inhalation comprising 1-methoxycarbonylpropyl) -8-ethyl-9-benzylpurine.
Ingredient weight / weight%
Micronized Compound of the Invention 1.0%
Micronized lactose99.0%
The components are melted and mixed to fill an inhaler with a dosing pump.
<Example 6>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- ( Described is a method for preparing a representative pharmaceutical composition in nebulized form, comprising 1-methoxycarbonylpropyl) -8-ethylpurine.
Ingredient weight / weight%
Compound of the Invention 0.005%
Water89.995%
Ethanol10.000%
The compound of the present invention is dissolved in ethanol and mixed with water. The formulation is then filled into a nebulizer with a dosing pump.
<Example 7>
This example provides a compound of the present invention or a pharmaceutically acceptable salt thereof, namely 2- (3-dimethylaminocarbonylphenoxy) -6- (2-phenoxy-4-amidinophenoxy) -9- ( A method of preparing a representative pharmaceutical composition in the form of aerosol, comprising 1-methoxycarbonylpropyl) -8-ethylpurine, is described.
Ingredient weight / weight%
Compound of the Invention0.10%
Propellant 11 / 1298.90%
Oleic Acid1.00%
The compounds of the present invention are dispersed in oleic acid and propellant. The resulting mixture is then placed in an aerosol container equipped with a meter.
<Example 8>
(In vitro analysis of factor Xa, thrombin and tissue plasminogen activator)
This assay demonstrates the activity of the compounds of the invention on factor Xa, thrombin and tissue plasminogen activator. The activity was measured at the initial rate of peptide p-nitroanilide cleavage by the enzyme. The cleavage product, p-nitroaniline, had a molar extinction coefficient of 9920 M ⁻¹ cm ⁻¹ at 405 nm.
Reagents and Solutions
Dimethyl sulfoxide (DMSO) (analytical)
Assay buffer: 50 mM TrisHCl, 150 mM NaCl, 2.5 mM CaCl ₂ and 0.1% polyethylene glycol 6000, pH 7.5
Enzyme (Enzyme Research Lab):
1. Human Factor Xa Stock: 0.281 mg / ml in assay buffer, stored at −80 ° C.
(Working solution (double dilution): 106 ng / ml or 2 nM in assay buffer, prepared before use)
2. Human thrombin stock: Store at -80 ° C. (working solution (double dilution): 1200 ng / ml or 40 nM in assay buffer, prepared before use)
3. Human Tissue Plasminogen Activator (tPA) (Two Chains, Sigma) Stock Solution: 1 mg / ml, Store at -80 ° C. (Working Solution (2x Dilution): 1361 ng / ml in Assay Buffer, use Before manufacture)
Chromosome Gene Substrate (Parmacia Heffer):
1.S222 (FXa assay) stock solution: 6 mM in dH ₂ O, stored at 4 ° C. (working solution (4-fold dilution): 656 μM in assay buffer)
2. S2302 (Thrombin Assay) Stock: 10 mM in dH ₂ O, stored at 4 ° C. (working solution (4-fold dilution): 1200 μM in assay buffer)
3. S2288 (tPA assay) stock solution: 10 mM in dH ₂ O, stored at 4 ° C. (working solution (4-fold dilution): 1484 μM in assay buffer)
(All substrate working solutions were prepared 5 days after analysis)
Standard Inhibitor Compound Stocks: Store at 5 mM, -20 ° C. in DMSO.
Test Compound (Compound of the Invention) Stock Solution: Store at 10 mM, -20 ° C in DMSO.
Analytical Method
Assays were performed in a total volume of 200 μl in 96-well microtiter plates. Analytical components were 50 mM TrisHCl, 150 mM NaCl, 2.5 mM CaCl 2, 0.1% polyethylene glycol 6000, pH 7.5 at final concentrations, and the concentrations of enzymes and substrates in the absence or presence of standard inhibitors or test compounds were as follows.
(1) 1 nM factor Xa and 164 μM S2222; (2) 20 nM thrombin and 300 μM S2302; And (3) 10 nM tPA and 371 μM S2288.
The concentration of standard inhibitor compound in the assay was 5 μM to 0.021 μM in 1-3 dilutions. The concentration of test compound in the assay was typically 10 μM to 0.041 μM in 1- to 3-fold dilutions. For efficacy test compounds, the concentration used for factor Xa analysis was further diluted to 100 fold (100 nM to 0.41 nM) or 1000 fold (10 nM to 0.041 nM). All substrate concentrations used were identical to their Km values under current assay conditions. Analysis was performed at room temperature.
The first step in the assay was to prepare 10 mM test compound stock in DMSO (for efficacy test compounds, 10 mM stock was further diluted to 0.1 or 0.01 for Factor Xa assays) and then biomec in 96 well plates. The working solution in which the 10 mM stock solution was serially diluted with 1000 (or multiprobe 204) is as follows:
(a) Diluted 1-250 fold of 10 mM stock in assay buffer to prepare 40 μM working solution: 1 to 100 and 1 to 2.5.
(b) 5 additional serial dilutions (1: 3) of 40 μM solution (each concentration is 600 μl). A total of six diluted test compound solutions were used in the analysis.
Standard inhibitor compounds (5 mM stock) or DMSO (control) used the same dilution steps as described for the test compounds.
The next step in the assay was to dispense 50 μl of the test compound working solution (4-fold dilution) (40 μM to 0.164 μM) into the microtiter plate twice using Biomec or MP204. To this, 100 μl of enzyme working solution (double dilution) was added using Biomec or MP204. The resulting solution was incubated for 10 minutes at room temperature.
50 μl of substrate working solution (4-fold dilution) was added to the solution using Biomec or MP204.
Enzyme kinetics were measured for 5 minutes at 10 seconds intervals at 405 nm in a THERMOmax plate reader at room temperature.
Calculation of Ki of the Test Substance
Enzyme rates were calculated in mOD / min based on the first 2 minutes reading. IC ₅₀ values were determined by calculating data for log-logit equations (linear) or Morrison equations (nonlinear) in an Excel spreadsheet. Subsequently, the IC ₅₀ value was divided by 2 to obtain a Ki value. Typically, Ki (factor Xa) values of less than 3 nM were calculated from the Morrison equation.
Compounds of the invention were tested in this assay to demonstrate the ability to selectively inhibit human factor Xa and human thrombin.
<Example 9>
(In vitro analysis of human prothrombinase)
This assay demonstrates that the compounds of the present invention can inhibit prothrombinase. Prothrombinase (PTase) catalyzes prothrombin activation to form fragment 1.2 and thrombin with mesothrombin as intermediate. This analysis is an endpoint analysis. The activity of prothrombinase is determined by the activity of thrombin (one of the reaction products) or the amount of thrombin formed over time based on the thrombin standard curve. In order to measure the IC ₅₀ (PTase) of the compounds of the present invention, PTase activity is expressed as thrombin activity (mOD / min).
material
enzyme:
1. Human Factor Va (Hematolologic Technology, Cat # HCVA-0110) Working Solution: Store at 1.0 mg / ml, 2 mM CaCl 2, -20 ° C. in 50% glycerol.
2. Human Factor Xa (Enzyme Research Lab Cat # HFXa 1011) Working Solution: 0.281 mg / ml (without BSA) in Assay Buffer, stored at -80 ° C.
3. Human Prothrombin (FII) (Enzyme Research Lab Cat # HFXa 1002) Working Solution: Dilute FII to 4.85 mg / ml in assay buffer (no BSA), stored at -80 ° C.
Phospholipid (PCPS) Packets:
PCPS vesicles (80% CP, 20% PS) were described in Barenolz et al., Biochemistry (1977), Vol. 16, pp 2806-2810 to make the modification by the method reported. Phosphatidylserine (Avanti Polar Lipiz, Cat # 840032): 10 mg / ml in chloroform, purified in brain, stored at −20 ° C. under nitrogen or argon.
Phospatadylcholine (Avanti Polar Lipiz, Cat # 850457): synthesized with 50 mg / ml, 16: 0-18: 1 palmitoyl-oleyl in chloroform, stored at −20 ° C. under nitrogen or argon.
Spectrozyme-TH (Cat # 238L, American Diagnostica): 50 micromoles, stored at room temperature Working solution: 50 micromoles in 10 ml of distilled water dissolved.
BSA (Sigma Chemicals Cat # A-7888, Fraction V, RIA grade)
Assay buffer: 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaCl 2, 0.1% PEG 6000 (BDH), 0.05% BSA (Sigma, Fraction V, RIA grade)
For single plate analysis, the following working solution was prepared.
Prothrombinase Complex:
(a) Diluted 27.5 μl of 100 μM PCPS (PCPS stock (4.36 mM) to final 1200 μl with assay buffer.
(b) 5.08 μl of 25 nM human factor Va: Va stock solution (1 mg / ml) was diluted to final 1200 μl with assay buffer.
(c) 5 pM human factor Xa: diluted 1: 1,220,000 of Xa stock (0.281 mg / ml) with assay buffer. Prepared at least 1200 μl.
Mix each component equally to 1100 μl in the order of PCPS, Va and Xa. Allow to stand at room temperature for 5-10 minutes and use immediately or store on ice (leave at room temperature before use).
2. 6 μM human prothrombin (FII): 124 μl of FII stock solution (4.85 mg / ml) was diluted to final 1400 μl with assay buffer.
3. 20 mM EDTA / assay buffer: Add 19.2 mL of assay buffer to 0.8 mL of 0.5 M EDTA, pH 8.5.
4. 0.2 mM Spectrozyme-TH / EDTA buffer: Add 0.44 mL of SPTH stock solution (5 mM) to 10.56 mL of 20 mM EDTA / assay buffer.
5. Test Compound (Compound of the Invention): Working solution (5-fold dilution) was prepared from 10 mM stock solution (DMSO) and diluted 1: 3 sequentially. Compounds were analyzed two at six concentrations.
Analytical Conditions and Methods:
The prothrombinase reaction was subjected to the final 50 of a mixture containing PTase (20 μM PCPS, 5 nM hFVa, and 1 pM hFXa), 1.2 μM human factor II and various concentrations of test compound (5 μM to 0.021 μM or low concentration range). In μl. The reaction was started by adding PTase and incubated for 6 minutes at room temperature. The reaction was stopped by adding EDTA / buffer to the final 10 mM. The activity of thrombin (product) was measured with a Thermomax microtiter reader at room temperature for 5 minutes (at intervals of 10 seconds) at 405 nm in the presence of 0.1 mM spectrozyme-TH as substrate. The reaction was carried out in 96-well microtiter plates.
In the first step of analysis, 10 ml of diluted test compound (5 times) or buffer was added to the plate twice. 10 μl of prothrombin (hFII) (5 ×) was added to each well. 30 μl of PTase was added to each well and mixed for about 30 seconds. Plates were incubated for 6 minutes at room temperature.
In the next step, 50 μl of 20 mM EDTA (in assay buffer) was added to each well to stop the reaction. The resulting solution was then mixed for about 10 seconds. 100 μl of 0.2 mM spectrozyme was added to each well. The thrombin reaction rate was then measured in a molecular device microplate reader at 405 nm for 5 minutes at 10 second intervals.
Calculation
The thrombin reaction rate was OD read from the 5 minute reaction and expressed in mOD / min. IC ₅₀ values were calculated using a log-logit curve.
Compounds of the invention have been tested in this assay to demonstrate that they can inhibit prothrombinase.
<Example 10>
(In vivo analysis)
The following assay demonstrates that the compound can act as an anticoagulant.
Male rats 250-330 g were anesthetized with sodium pentobarbital (90 mg / kg, intravenously) and prepared for surgical operation. The left carotid artery was inserted with a cannula to take blood samples to monitor blood pressure and monitor coagulation parameters (prothrombin time (PT) and activated partial thromboplastin time (aPTT). Compounds and Standards of the Invention) The cannula was inserted for administration and thromboplastin injection, opening the abdomen with a midline incision and ligating the abdominal vein into 2-3 cm pieces from the renal vein. The test compound was administered as an intravenous pill (t = 0) After 3 minutes (t = 3) the thromboplastin infusion was initiated After the 2 minute infusion (t = 5), the abdomen The veins were ligated to the distal and opposite ends The vessels were allowed to stand for 60 minutes, then cut out of the animal, incised, carefully removed the thrombus (if present) and weighed.The statistical analysis of the results was Wilcoxin-Match De- It was performed using the Wilcoxin-matched-pairs signed rank test.
Compounds of the invention have been tested in this assay to demonstrate that they can inhibit coagulation.
While the invention has been described in terms of specific embodiments, it will be understood by those skilled in the art that various modifications are possible and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications are possible and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to particular circumstances, materials, compositions, methods, step (s) within the spirit, scope and scope of the invention. All such modifications are possible within the scope of the appended claims.

权利要求:
Claims (10)
[1" claim-type="Currently amended] A compound selected from the group consisting of compounds of the formulas (I) to (IV), as a sole stereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.
<Formula I>

<Formula II>

<Formula III>

<Formula IV>

In the above formula,
Z ¹ and Z ² are independently —O—, —N (R ¹⁰ ) — or —OCH ₂ —,
R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) C (O) R ¹⁰ , or -N (H) S (O) ₂ R ¹³ ,
R ² is -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C (NH) N (H) C (O) OR ¹³ , -C (NH) N (H) C ( O) R ¹⁰ , -C- (NH) N (H) S (O) ₂ R ¹³ , or -C (NH) N (H) C (O) N (H) R ¹⁰ ,
R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C ( O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2 ) -Tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally by alkyl) Substituted),
R ⁵ is hydrogen, halo, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, alkylthio, hydroxy, mercapto, alkoxy, or —N (R ¹⁰ ) R ¹¹ ,
R ⁶ is — (C (R ⁷ ) (R ⁸ )) _n —R ⁹ (where n is 1 to 4), hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, Amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydride) Oxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl)
Wherein each R ⁷ is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, -C (O) OR ¹⁰ , -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -C- (O) -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) R ¹⁰ , -R ^12- C (O) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (OR ¹⁰ ) -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (R ¹⁰ ) (OR ¹⁰ ) C (O) OR ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -C (R ¹⁰ ) (OR ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹³ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ ,- R ¹² -N (R ¹⁰ ) S (O) ₂ R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -N (R ¹⁰ ) S (O) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -ON (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -OS (O) ₂ OR ¹⁰ , -R ¹² -P (O) (OR ¹⁰ ) R ¹¹ , -R ¹² -OP (O) ( OR ¹⁰ ) ₂ , -R ¹² -P (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -SR ¹² -C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -SR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) R ¹⁰ , -R ¹² -SSR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (0) OR ¹⁰ , -R ¹² -SC (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -SC (S) N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) R ¹⁰ , -R ¹² -S (O) ₂ R ¹³ , -R ¹² -S (O) OR ¹⁰ , -R ¹² -S (O) ₂ OR ¹⁰ , -R ¹² -S (O) ₂ N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) (NR ¹⁰ ) R ^11, or
Or each R ⁷ is aryl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N ( R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ is substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclyl (optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N ( R ¹⁰ ) R ¹¹ , -C- (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of ), Or
Or each R ⁷ is adamantyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is adamantylalkyl, wherein the adamantyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S- (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ , which is substituted with one or more substituents selected from the group consisting of ,
Each R ⁸ is independently hydrogen, alkyl, cycloalkyl, or aryl,
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ,
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), and
R ¹² is straight or branched alkylene,
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).
[2" claim-type="Currently amended] The compound of claim 1, wherein Z ¹ and Z ² are independently —O— or —OCH ₂ —;
R ¹ and R ⁴ are each independently hydrogen, halo or -OR ¹⁰ ;
R ² is —C (NH) NH ₂ , —C (NH) N (H) S (O) ₂ R ¹³ , or —C (NH) N (H) C (O) N (H) R ¹⁰ ;
R ³ is ureido, guanidino, -C (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -N- (R ¹⁰ ) C (O ) R ¹⁰ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -already Dazolinyl (optionally substituted by alkyl);
R ⁵ is hydrogen, halo, alkyl, haloalkyl, aryl, or aralkyl;
R ⁶ is alkyl, aryl, aralkyl, or-(C (R ⁷ ) (R ⁸ )) _n -R ⁹ , where n is 1;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C- (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of ego;
R ⁸ is independently hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
R ¹² is straight or branched alkylene;
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).
[3" claim-type="Currently amended] The compound of claim 2, wherein Z ¹ and Z ² are each —O—;
R ¹ is hydrogen or —OR ¹⁰ ;
R ² is —C (NH) NH ₂ ;
R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally by alkyl Substituted), or (1,2) -imidazolinyl (optionally substituted by alkyl);
R ⁴ is hydrogen;
R ⁵ is alkyl or aralkyl;
R ⁶ is alkyl, aralkyl, or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, hydroxy, and -OP (O) (OR ¹⁰ ) ₂ ),
Or R ⁷ is imidazolylalkyl or indolylalkyl;
R ⁸ is hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is alkyl or aryl.
[4" claim-type="Currently amended] The compound of claim 3, wherein Z ¹ and Z ² are each —O—;
R ¹ is hydrogen;
R ² is —C (NH) NH ₂ ;
R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally by alkyl Substituted), or (1,2) -imidazolinyl (optionally substituted by alkyl);
R ⁴ is hydrogen;
R ⁵ is alkyl;
R ⁶ is aralkyl or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ^13, or
Or R ⁷ is aralkyl (optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, hydroxy, and -OP (O) (OR ¹⁰ ) ₂ ),
Or R ⁷ is imidazolylalkyl or indolylalkyl;
R ⁸ is hydrogen or alkyl;
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is alkyl or aryl.
[5" claim-type="Currently amended] The compound of claim 4, wherein R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , (1,2) -imidazolyl (optionally substituted by alkyl) or (1,2) -imidazolinyl (Optionally substituted by alkyl);
R ⁴ is hydrogen;
R ⁵ is alkyl;
R ⁶ is aralkyl or —C (R ⁷ ) (R ⁸ ) -R ⁹ ;
R ⁷ is alkyl, -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -OP (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -S (O) ₂ R ¹³ ;
R ⁸ is hydrogen;
R ⁹ is —C (O) OR ¹⁰ ;
R ¹⁰ and R ¹¹ are each independently hydrogen or alkyl;
R ¹² is straight or branched alkylene;
R ¹³ is alkyl or aryl.
[6" claim-type="Currently amended] The compound of claim 5, wherein R ³ is —C (O) N (R ¹⁰ ) R ¹¹ ;
R ⁴ is hydrogen;
R ⁵ is methyl or ethyl;
R ⁶ is benzyl;
R ¹⁰ and R ¹¹ are independently hydrogen or methyl.
[7" claim-type="Currently amended] The compound of claim 6, wherein R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , wherein R ¹⁰ and R ¹¹ are both methyl, R ⁴ is hydrogen, R ⁵ is methyl, and R ⁶ Is benzyl, i.e. 2- (2-hydroxy-5-amidinophenoxy) -6- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine
[8" claim-type="Currently amended] The compound of claim 6, wherein R ³ is —C (O) N (R ¹⁰ ) R ¹¹ , wherein R ¹⁰ and R ¹¹ are both methyl, R ⁴ is hydrogen, R ⁵ is methyl, and R ⁶ Is benzyl, ie 6- (2-hydroxy-5-amidinophenoxy) -2- (3-dimethylaminocarbonylphenoxy) -8-methyl-9-benzylpurine.
[9" claim-type="Currently amended] Characteristics of thrombus activity, including a therapeutically effective amount of a compound selected from the group consisting of compounds of Formulas (I) to (IV), as a sole stereoisomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient Pharmaceutical compositions useful for treating a person having a disease state having.
<Formula I>

<Formula II>

<Formula III>

<Formula IV>

In the above formula,
Z ¹ and Z ² are independently —O—, —N (R ¹⁰ ) — or —OCH ₂ —,
R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) C (O) R ¹⁰ , or -N (H) S (O) ₂ R ¹³ ,
R ² is -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C (NH) N (H) C (O) OR ¹³ , -C (NH) N (H) C ( O) R ¹⁰ , -C- (NH) N (H) S (O) ₂ R ¹³ , or -C (NH) N (H) C (O) N (H) R ¹⁰ ,
R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C ( O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2 ) -Tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally by alkyl) Substituted),
R ⁵ is hydrogen, halo, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, alkylthio, hydroxy, mercapto, alkoxy, or —N (R ¹⁰ ) R ¹¹ ,
R ⁶ is — (C (R ⁷ ) (R ⁸ )) _n —R ⁹ (where n is 1 to 4), hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, Amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydride) Oxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl)
Wherein each R ⁷ is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, -C (O) OR ¹⁰ , -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -C- (O) -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) R ¹⁰ , -R ^12- C (O) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (OR ¹⁰ ) -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (R ¹⁰ ) (OR ¹⁰ ) C (O) OR ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -C (R ¹⁰ ) (OR ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹³ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ ,- R ¹² -N (R ¹⁰ ) S (O) ₂ R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -N (R ¹⁰ ) S (O) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -ON (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -OS (O) ₂ OR ¹⁰ , -R ¹² -P (O) (OR ¹⁰ ) R ¹¹ , -R ¹² -OP (O) ( OR ¹⁰ ) ₂ , -R ¹² -P (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -SR ¹² -C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -SR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) R ¹⁰ , -R ¹² -SSR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (0) OR ¹⁰ , -R ¹² -SC (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -SC (S) N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) R ¹⁰ , -R ¹² -S (O) ₂ R ¹³ , -R ¹² -S (O) OR ¹⁰ , -R ¹² -S (O) ₂ OR ¹⁰ , -R ¹² -S (O) ₂ N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) (NR ¹⁰ ) R ^11, or
Or each R ⁷ is aryl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N ( R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ is substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclyl (optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N ( R ¹⁰ ) R ¹¹ , -C- (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of ), Or
Or each R ⁷ is adamantyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is adamantylalkyl, wherein the adamantyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S- (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ , which is substituted with one or more substituents selected from the group consisting of ,
Each R ⁸ is independently hydrogen, alkyl, cycloalkyl, or aryl,
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ,
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), and
R ¹² is straight or branched alkylene,
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).
[10" claim-type="Currently amended] Characterizing thrombotic activity, comprising administering to a person in need thereof a therapeutically effective amount of a compound selected from the group consisting of compounds of Formulas (I) to (IV), or as a mixture thereof, alone or as a mixture thereof. A method of treating a person with a diseased condition.
<Formula I>

<Formula II>

<Formula III>

<Formula IV>

In the above formula,
Z ¹ and Z ² are independently —O—, —N (R ¹⁰ ) — or —OCH ₂ —,
R ¹ and R ⁴ are each independently hydrogen, halo, alkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) C (O) R ¹⁰ , or -N (H) S (O) ₂ R ¹³ ,
R ² is -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C (NH) N (H) C (O) OR ¹³ , -C (NH) N (H) C ( O) R ¹⁰ , -C- (NH) N (H) S (O) ₂ R ¹³ , or -C (NH) N (H) C (O) N (H) R ¹⁰ ,
R ³ is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, -OR ¹⁰ , -C (NH) NH ₂ , -C (NH) N (H) OR ¹⁰ , -C ( O) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -CH (OH) C- (O) N (R ¹⁰ ) R ¹¹ , -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , R ¹² -C (O) OR ¹⁰ , -N (R ¹⁰ ) C (O) R ¹⁰ , (1,2 ) -Tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2) -imidazolyl (optionally substituted by alkyl), or (1,2) -imidazolinyl (optionally by alkyl) Substituted),
R ⁵ is hydrogen, halo, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, alkylthio, hydroxy, mercapto, alkoxy, or —N (R ¹⁰ ) R ¹¹ ,
R ⁶ is — (C (R ⁷ ) (R ⁸ )) _n —R ⁹ (where n is 1 to 4), hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, Amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydride) Oxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl)
Wherein each R ⁷ is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, -C (O) OR ¹⁰ , -R ¹² -C (O) OR ¹⁰ , -R ¹² -C (O) N (R ¹⁰ ) R ¹¹ , -C- (O) -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -C (O) R ¹⁰ , -R ^12- C (O) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -C (R ¹⁰ ) (OR ¹⁰ ) -R ¹² -N (R ¹⁰ ) R ¹¹ , -C (R ¹⁰ ) (OR ¹⁰ ) C (O) OR ¹¹ , -R ¹² -C (R ¹⁰ ) (C (O) OR ¹⁰ ) ₂ , -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -C (R ¹⁰ ) (OR ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹³ , -R ¹² -N (R ¹⁰ ) C (O) OR ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) R ¹³ ,- R ¹² -N (R ¹⁰ ) S (O) ₂ R ¹³ , -R ¹² -N (R ¹⁰ ) C (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -N (R ¹⁰ ) -R ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -N (R ¹⁰ ) S (O) R ¹¹ , -R ¹² OR ¹⁰ , -R ¹² -ON (R ¹⁰ ) C (NR ¹⁰ ) N (R ¹⁰ ) R ¹¹ , -R ¹² -OS (O) ₂ OR ¹⁰ , -R ¹² -P (O) (OR ¹⁰ ) R ¹¹ , -R ¹² -OP (O) ( OR ¹⁰ ) ₂ , -R ¹² -P (O) (OR ¹⁰ ) ₂ , -R ¹² -SR ¹⁰ , -R ¹² -SR ¹² -C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) R ¹¹ , -R ¹² -SR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) OR ¹⁰ , -R ¹² -SR ¹² -N (R ¹⁰ ) C (O) R ¹⁰ , -R ¹² -SSR ¹² -C (R ¹⁰ ) (N (R ¹⁰ ) R ¹¹ ) C (0) OR ¹⁰ , -R ¹² -SC (O) N (R ¹⁰ ) R ¹¹ , -R ¹² -SC (S) N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) R ¹⁰ , -R ¹² -S (O) ₂ R ¹³ , -R ¹² -S (O) OR ¹⁰ , -R ¹² -S (O) ₂ OR ¹⁰ , -R ¹² -S (O) ₂ N (R ¹⁰ ) R ¹¹ , -R ¹² -S (O) (NR ¹⁰ ) R ^11, or
Or each R ⁷ is aryl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N ( R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ is substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is aralkyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) OR ¹⁰ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclyl (optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N Or (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is heterocyclylalkyl, wherein the heterocyclyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, aralkyl, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N ( R ¹⁰ ) R ¹¹ , -C- (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ substituted with one or more substituents selected from the group consisting of ), Or
Or each R ⁷ is adamantyl (optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S (O) ₂ OR ^10, and -OP (O) (OR ¹⁰ ) ₂ and substituted with one or more substituents selected from the group consisting of:
Or each R ⁷ is adamantylalkyl, wherein the adamantyl radical is optionally alkyl, halo, haloalkyl, haloalkoxy, -OR ¹⁰ , -SR ¹⁰ , -C (O) OR ¹⁰ , -N (R ¹⁰ ) R ¹¹ , -C (O) N (R ¹⁰ ) R ¹¹ , -S- (O) ₂ OR ¹⁰ and -OP (O) (OR ¹⁰ ) ₂ , which is substituted with one or more substituents selected from the group consisting of ,
Each R ⁸ is independently hydrogen, alkyl, cycloalkyl, or aryl,
R ⁹ is —C (O) OR ¹⁰ or —C (O) N (R ¹⁰ ) R ¹¹ ,
R ¹⁰ and R ¹¹ are each independently hydrogen, alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, mono Alkylaminocarbonyl, or substituted by dialkylaminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbons) Carbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), and
R ¹² is straight or branched alkylene,
R ¹³ is alkyl, aryl (optionally halo, alkyl, hydroxy, alkoxy, aralkyloxy, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkyl Substituted by aminocarbonyl), or aralkyl (optionally halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkyl Aminocarbonyl, or substituted by dialkylaminocarbonyl).

类似技术:

---

公开号 | 公开日 | 专利标题

---

DE69630214T2|2004-07-15|Benzamidine derivatives, their production and their use as anti-coagulants

---

EP0708768B1|2003-04-09|Tri-substituted imidazoles having multiple therapeutic properties

---

EP1208097B1|2009-02-18|Substituted oxoazaheterocyclyl compounds

---

ES2215337T3|2004-10-01|Orto-antranilamide derivatives as anticoagulants.

---

EP1383731B1|2009-08-05|Biaryl compounds as serine protease inhibitors

---

AU2005226359B2|2011-02-03|9-substituted 8-oxoadenine compound

---

US7754750B2|2010-07-13|Metalloproteinase inhibitors

---

AU732969B2|2001-05-03|-heterocyclic derivatives as NOS inhibitors

---

EP1608645B1|2007-05-02|Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses

---

EP1539710B1|2010-10-27|Heterocyclic derivatives

---

US8101615B2|2012-01-24|1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

---

DE69730490T2|2005-09-29|Amino-etherocyclic compounds as antithrombotic or anticoagulating agent

---

US5276049A|1994-01-04|Cyclic urea derivatives, pharmaceutical compositions containing these compounds and methods of using the same

---

KR101979050B1|2019-05-15|Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases

---

EP1864979B1|2011-09-07|Imidazole-derivatives as TAFAIa-inhibitors

---

RU2386629C2|2010-04-20|New hydantoic derivatives for treating obstructive airway diseases

---

US5962695A|1999-10-05|Aromatic amidine derivatives and salts thereof

---

EP3113772B1|2020-09-09|Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors

---

KR100223135B1|1999-10-15|Cyclic imino derivatives, process for their preparation and drugs containing them

---

KR100837420B1|2008-06-12|5-Hydroxyindole-3-carboxylates derivatives and their use

---

US6638980B1|2003-10-28|Inhibitors of factor Xa

---

US6538015B1|2003-03-25|Anti-HIV pyrazole derivatives

---

US6545055B1|2003-04-08|Inhibitors of factor Xa

---

EP1355887B1|2007-08-15|Pyrimidine acyclonucleoside derivatives, preparation method and use thereof

---

US5691335A|1997-11-25|Imidazolidine derivative and use thereof

同族专利:

---

公开号 | 公开日

---

HK1020057A1|2003-08-29|

---

NO990673D0|1999-02-12|

---

SK19399A3|1999-08-06|

---

IL128160A|2003-04-10|

---

CZ50299A3|1999-06-16|

---

PT920430E|2003-12-31|

---

DE69725151D1|2003-10-30|

---

CA2262876A1|1998-02-26|

---

CN1228092A|1999-09-08|

---

US5753635A|1998-05-19|

---

NO990673L|1999-04-15|

---

RU2191778C2|2002-10-27|

---

ES2206746T3|2004-05-16|

---

AU4118697A|1998-03-06|

---

EP0920430A1|1999-06-09|

---

WO1998007725A1|1998-02-26|

---

PL331608A1|1999-08-02|

---

DE69725151T2|2004-06-09|

---

HU9902308A2|2000-07-28|

---

HU9902308A3|2000-08-28|

---

IL128160D0|1999-11-30|

---

JP2000516242A|2000-12-05|

---

AU722631B2|2000-08-10|

---

EP0920430B1|2003-09-24|

---

DK920430T3|

---

DK0920430T3|2003-11-17|

---

NZ333895A|2000-07-28|

---

AT250606T|2003-10-15|

---

CN1096461C|2002-12-18|

---

NO314584B1|2003-04-14|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1996-08-16|Priority to US08/689,979

---

1996-08-16|Priority to US8/689,979

---

1997-08-14|Application filed by 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만, 쉐링 악티엔게젤샤프트

---

2000-11-25|Publication of KR20000068177A

优先权:

---

申请号 | 申请日 | 专利标题

---

US08/689,979|US5753635A|1996-08-16|1996-08-16|Purine derivatives and their use as anti-coagulants|

---

US8/689,979|1996-08-16|